[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 643
1. Chan ES, Ng CF, Chui KL, Lo KL, Hou SM, Yip SK: Novel approach of laparoscopic transperitoneal en bloc resection of urachal tumor and umbilectomy with a comparison of various techniques. J Laparoendosc Adv Surg Tech A; 2009 Jun;19(3):423-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Urachal carcinoma is a rare cancer that accounts for less than 1% of all bladder cancers.
  • [MeSH-major] Adenocarcinoma / surgery. Laparoscopy / methods. Umbilicus / surgery. Urachus / surgery. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19405800.001).
  • [ISSN] 1092-6429
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Jasperson KW, Blazer KR, Lowstuter K, Weitzel JN: Working through a diagnostic challenge: colonic polyposis, Amsterdam criteria, and a mismatch repair mutation. Fam Cancer; 2008;7(4):281-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The two most common causes of hereditary colorectal cancer are Lynch syndrome and familial adenomatous polyposis (FAP).
  • The phenotype of Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC), is differentiated in part from FAP by the lack of profuse colonic polyposis.
  • Here we describe a proband who presented with greater than 50 adenomatous colonic polyps prior to developing cancer of the colon and urinary bladder, and a family history that fulfills the Amsterdam criteria.
  • Germline analyses of APC and MYH in the proband did not reveal any mutations.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenomatous Polyposis Coli / complications. Colonic Neoplasms / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / diagnosis. DNA-Binding Proteins
  • [MeSH-minor] Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / genetics. Female. Genes, APC. Germ-Line Mutation. Humans. Middle Aged. Neoplasms, Multiple Primary / genetics. Pedigree. Phenotype. Urinary Bladder Neoplasms / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2002 Jul;97(7):1822-7 [12135043.001]
  • [Cites] Clin Genet. 1998 Oct;54(4):368-70 [9831355.001]
  • [Cites] Gut. 1997 Aug;41(2):235-8 [9301504.001]
  • [Cites] Gene. 2001 Jul 11;272(1-2):301-13 [11470537.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1453-6 [10348829.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):42-8 [14699485.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):721-33 [11257105.001]
  • [Cites] Hum Mutat. 2004 Mar;23(3):285 [14974087.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):807-14 [16557584.001]
  • [Cites] Int J Colorectal Dis. 2006 Jan;21(1):79-83 [16676398.001]
  • [Cites] J Med Genet. 1999 Oct;36(10 ):790-3 [10528862.001]
  • [Cites] Dis Colon Rectum. 1991 May;34(5):424-5 [2022152.001]
  • [Cites] Int J Colorectal Dis. 2006 Dec;21(8):847-50 [16525781.001]
  • [Cites] J Bacteriol. 1994 Sep;176(17):5393-400 [8071216.001]
  • [Cites] Hum Genet. 2006 Mar;119(1-2):206-11 [16408224.001]
  • [Cites] Gut. 2003 Jun;52(6):898-9 [12740349.001]
  • [Cites] Fam Cancer. 2007;6(1):43-51 [17039270.001]
  • [Cites] Fam Cancer. 2003;2(1):43-55 [14574166.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Oct;3(10):1022-8 [16234049.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):11135-42 [11801590.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5908-13 [12732731.001]
  • [Cites] Int J Cancer. 2002 Feb 10;97(5):643-8 [11807791.001]
  • (PMID = 18176851.001).
  • [ISSN] 1389-9600
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000043; United States / NCI NIH HHS / CA / R25 CA085771; United States / NCRR NIH HHS / RR / M01 RR00043; United States / NCI NIH HHS / CA / R25 CA85771
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein
  •  go-up   go-down


3. Higgins JP, Kaygusuz G, Wang L, Montgomery K, Mason V, Zhu SX, Marinelli RJ, Presti JC Jr, van de Rijn M, Brooks JD: Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol; 2007 May;31(5):673-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To identify novel diagnostic markers that may aid in the differential diagnosis of prostate versus urothelial carcinoma, we analyzed expression patterns in prostate and bladder cancer tissues using complementary DNA microarrays.
  • We conclude that the detection of S100P and GATA3 protein expression may help distinguish urothelial carcinomas from other genitourinary neoplasms that enter into the differential diagnosis.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Calcium-Binding Proteins / metabolism. Carcinoma, Transitional Cell / metabolism. GATA3 Transcription Factor / metabolism. Neoplasm Proteins / metabolism. Urologic Neoplasms / metabolism
  • [MeSH-minor] Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. DNA, Neoplasm / analysis. Diagnosis, Differential. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Kidney Neoplasms / genetics. Kidney Neoplasms / metabolism. Kidney Neoplasms / pathology. Male. Nephrectomy. Oligonucleotide Array Sequence Analysis. Prostatic Neoplasms / genetics. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Tissue Array Analysis. Urinary Bladder Neoplasms / genetics. Urinary Bladder Neoplasms / metabolism. Urinary Bladder Neoplasms / pathology. Urothelium / metabolism. Urothelium / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460449.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / DNA, Neoplasm; 0 / GATA3 Transcription Factor; 0 / GATA3 protein, human; 0 / Neoplasm Proteins; 0 / S100P protein, human
  •  go-up   go-down


Advertisement
4. Oh SJ, Lee SJ, Lee HY, Paik YH, Lee DK, Lee KS, Chung JB, Yu JS, Yoon DS: [Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas]. Korean J Gastroenterol; 2009 Sep;54(3):162-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five, six, and two extrapancreatic malignancies had been diagnosed before, during, and after the diagnosis of IPMN.
  • Gastric adenocarcinoma (3 patients, 23%) and colorectal carcinoma (3 patients, 23%) were the most common neoplasms.
  • Other extrapancreatic tumors included lung cancer (n=2), prostatic cancer (n=1), renal cell carcinoma (n=1), cholangiocellular carcinoma (n=1), urinary bladder cancer (n=1), and gallbladder cancer (n=1), respectively.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Neoplasms, Multiple Primary / epidemiology. Neoplasms, Second Primary / epidemiology. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Korean J Gastroenterol. 2009 Sep;54(3):196-8 [19844158.001]
  • (PMID = 19844152.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


5. Marino G, Motta E, Mosso L, Bocca C, Ravarino N, Torchio B: Primary signet ring cell adenocarcinoma of the bladder. Minerva Urol Nefrol; 2005 Jun;57(2):125-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary signet ring cell adenocarcinoma of the bladder.
  • [MeSH-major] Carcinoma, Signet Ring Cell. Urinary Bladder Neoplasms
  • [MeSH-minor] Aged. Cystectomy. Humans. Male. Urethra / surgery. Urinary Diversion

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951737.001).
  • [ISSN] 0393-2249
  • [Journal-full-title] Minerva urologica e nefrologica = The Italian journal of urology and nephrology
  • [ISO-abbreviation] Minerva Urol Nefrol
  • [Language] eng; ita
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Italy
  •  go-up   go-down


6. Giordano S, Taskinen S, Sankila A, Ala-Opas M: Adenocarcinoma in isolated rectal bladder after treatment of bladder exstrophy. Scand J Urol Nephrol; 2008;42(4):392-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in isolated rectal bladder after treatment of bladder exstrophy.
  • We report the first Finnish patient with carcinoma in an augmented intestinal bladder, where urine and stools are not in contact.
  • The patient had undergone rectal bladder reconstruction at the age of 2 years because of bladder exstrophy.
  • When the patient was aged 46 years, a 2-cm, papillar, well-differentiated adenocarcinoma was detected and removed, preserving the rectal bladder.
  • [MeSH-major] Adenocarcinoma / diagnosis. Bladder Exstrophy. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Child, Preschool. Humans. Male. Rectum / surgery. Urinary Bladder / abnormalities. Urinary Bladder / surgery

  • Genetic Alliance. consumer health - Exstrophy of the Bladder.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19230174.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


7. Sasaki M, Kobayashi T, Ono K, Sugano O, Sasao S, Hoshi S: [Small cell carcinoma of the prostate: a case report]. Hinyokika Kiyo; 2006 Sep;52(9):719-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 79-year-old man was admitted to our department with a chief complaint of urinary incontinence.
  • We performed a prostate biopsy and histological examinations indicated poorly differentiated adenocarcinoma with a Gleason score of 5+5=10.
  • A computed tomographic (CT) scan revealed a prostatic tumor invading the bladder, seminal vesicle and rectum.
  • He was diagnosed with a stage T4N1M0 adenocarcinoma of the prostate.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17040059.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


8. Zantl N, Gschwend JE: [Value of cystoprostatectomy in locally advanced prostate carcinoma]. Urologe A; 2008 Nov;47(11):1447-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • According to the literature cancer-specific 10-year survival rates are 38% or median cancer-specific survival lies between 24 and 31 months.
  • The role of neoadjuvant or adjuvant hormonal therapy, chemotherapy, or radiotherapy has not yet been defined.
  • Mostly after cystoprostatectomy due to locally advanced prostate carcinoma an ileal conduit is formed for urinary diversion, but also orthotopic neobladders or continent pouches are used.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Disease-Free Survival. Humans. Lymph Node Excision. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery. Palliative Care. Quality of Life. Salvage Therapy. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery. Urinary Reservoirs, Continent

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2005 Mar;173(3):781-3 [15711269.001]
  • [Cites] Eur Urol. 2007 Oct;52(4):1058-65 [17418938.001]
  • [Cites] BJU Int. 2005 Apr;95(6):794-8 [15794785.001]
  • [Cites] Urology. 1997 Oct;50(4):580-4 [9338735.001]
  • [Cites] Urology. 2005 Oct;66(4):824-9 [16230146.001]
  • [Cites] J Urol. 2005 Apr;173(4):1156-60 [15758726.001]
  • [Cites] J Urol. 2000 Jun;163(6):1771-4 [10799179.001]
  • [Cites] J Urol. 1998 Jul;160(1):29-33 [9628599.001]
  • [Cites] Urologe A. 2006 Oct;45(10):1260-5 [16983529.001]
  • [Cites] J Urol. 1988 Sep;140(3):544-9 [3411670.001]
  • [Cites] J Urol. 2005 Dec;174(6):2186-90 [16280761.001]
  • [Cites] J Urol. 1995 Jan;153(1):104-10 [7526002.001]
  • [Cites] Aktuelle Urol. 2003 Jul;34(4):259-61 [14566679.001]
  • [Cites] Am J Public Health. 2001 Jan;91(1):126-8 [11189804.001]
  • [Cites] Urologe A. 2004 Feb;43(2):172-7 [14991119.001]
  • [Cites] J Urol. 2003 Nov;170(5):1868-71 [14532795.001]
  • [Cites] Urologe A. 2006 Apr;45(4):474-81 [16465521.001]
  • [Cites] Urology. 1998 May;51(5):789-95 [9610593.001]
  • (PMID = 18810382.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


9. Eissa S, Zohny SF, Zekri AR, El-Zayat TM, Maher AM: Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence. Med Oncol; 2010 Dec;27(4):1286-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence.
  • Development of new methods for bladder cancer detection is required because cystoscopy is invasive, and voided urine cytology (VUC) has low sensitivity.
  • The aim of this study was to evaluate the diagnostic performance of urinary fibronectin and mutant p53 in comparison with VUC in the detection of bladder cancer.
  • This study included 100 patients diagnosed with bladder cancer, 93 patients with benign urological disorders and 47 healthy volunteers.
  • Our results indicate that fibronectin had the highest sensitivity compared to VUC and mutant p53 in bladder cancer detection; however, mutant p53 had superior specificity compared to VUC and fibronectin.
  • Mutant p53 is associated with disease recurrence and hence it has a significant prognostic role in bladder cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Transitional Cell / diagnosis. Fibronectins / urine. Mutation / genetics. Tumor Suppressor Protein p53 / genetics. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Animals. Biomarkers, Tumor / genetics. Biomarkers, Tumor / urine. Case-Control Studies. Cystoscopy. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / urine. Neoplasm Staging. Polymerase Chain Reaction. Prognosis. ROC Curve. Schistosoma mansoni / pathogenicity. Schistosomiasis / diagnosis. Schistosomiasis / genetics. Schistosomiasis / urine. Sensitivity and Specificity. Survival Rate. Urinary Bladder / metabolism. Urinary Bladder / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Urol. 2007 Jun;25(3):285-95 [17530260.001]
  • [Cites] World J Urol. 2009 Feb;27(1):9-20 [19039591.001]
  • [Cites] Ann Trop Med Parasitol. 1991 Dec;85(6):599-604 [1811437.001]
  • [Cites] Clin Chim Acta. 2004 Feb;340(1-2):57-65 [14734196.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):136-41 [10638980.001]
  • [Cites] Radiology. 1982 Apr;143(1):29-36 [7063747.001]
  • [Cites] Urol Oncol. 2003 Sep-Oct;21(5):334-41 [14670539.001]
  • [Cites] Eur Urol. 2003 Dec;44(6):687-94 [14644121.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):171-9 [11801555.001]
  • [Cites] Urology. 2005 Feb;65(2):284-9 [15708039.001]
  • [Cites] Matrix Biol. 2005 Sep;24(6):389-99 [16061370.001]
  • [Cites] Clin Biochem. 2008 Nov;41(16-17):1335-41 [18804101.001]
  • [Cites] Clin Chem. 1998 Jul;44(7):1397-403 [9665415.001]
  • [Cites] Clin Chem. 1996 Jun;42(6 Pt 1):858-68 [8665676.001]
  • [Cites] J Urol. 2002 Aug;168(2):465-9 [12131289.001]
  • [Cites] World J Gastroenterol. 2003 Jul;9(7):1444-9 [12854138.001]
  • [Cites] Carcinogenesis. 2004 Dec;25(12):2319-23 [15308588.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2127-35 [11391594.001]
  • [Cites] Clin Chim Acta. 1993 Aug 31;217(2):115-28 [8261621.001]
  • [Cites] Eur Urol. 2001 Mar;39(3):292-9 [11275722.001]
  • [Cites] Science. 1945 May 18;101(2629):519-20 [17775845.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7530-8 [14612556.001]
  • (PMID = 20012564.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Fibronectins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


10. Hu SC, Chen GS, Wu CS, Chai CY, Chen WT, Lan CC: Rates of cutaneous metastases from different internal malignancies: experience from a Taiwanese medical center. J Am Acad Dermatol; 2009 Mar;60(3):379-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the rate of cutaneous metastasis from breast cancer was much lower compared with previous studies involving Caucasians.
  • In addition, the expressions of CCR10 and CXCR4 by tumor cells did not correlate well with the presence or absence of skin metastases.
  • [MeSH-major] Adenocarcinoma / ethnology. Adenocarcinoma / secondary. Breast Neoplasms / ethnology. Breast Neoplasms / pathology. Skin Neoplasms / ethnology. Skin Neoplasms / secondary
  • [MeSH-minor] Academic Medical Centers / statistics & numerical data. Asian Continental Ancestry Group / statistics & numerical data. Carcinoma, Hepatocellular / ethnology. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / secondary. Carcinoma, Squamous Cell / ethnology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / ethnology. Carcinoma, Transitional Cell / metabolism. Carcinoma, Transitional Cell / secondary. Gastrointestinal Neoplasms / ethnology. Gastrointestinal Neoplasms / metabolism. Gastrointestinal Neoplasms / pathology. Humans. Immunohistochemistry. Liver Neoplasms / ethnology. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Lung Neoplasms / ethnology. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Mouth Neoplasms / ethnology. Mouth Neoplasms / metabolism. Mouth Neoplasms / pathology. Receptors, CCR10 / metabolism. Receptors, CXCR4 / metabolism. Retrospective Studies. Taiwan / epidemiology. Urinary Bladder Neoplasms / ethnology. Urinary Bladder Neoplasms / metabolism. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19056145.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCR10 protein, human; 0 / CXCR4 protein, human; 0 / Receptors, CCR10; 0 / Receptors, CXCR4
  •  go-up   go-down


11. Norkus D, Miller A, Kurtinaitis J, Haverkamp U, Popov S, Prott FJ, Valuckas KP: A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma : a report on acute toxicity. Strahlenther Onkol; 2009 Nov;185(11):715-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma : a report on acute toxicity.
  • PURPOSE: To compare acute gastrointestinal (GI) and genitourinary (GU) toxicity between patient groups with localized prostate adenocarcinoma, treated with conventionally fractionated (CFRT) and hypofractionated (HFRT) three-dimensional conformal external-beam radiotherapy (3D-CRT).
  • [MeSH-major] Adenocarcinoma / radiotherapy. Dose Fractionation. Gastrointestinal Tract / radiation effects. Prostatic Neoplasms / radiotherapy. Radiation Injuries / etiology. Radiotherapy Planning, Computer-Assisted / methods. Urogenital System / radiation effects
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Disease-Free Survival. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Lithuania. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Prostate / radiation effects. Prostate-Specific Antigen / blood. Radiotherapy Dosage. Radiotherapy, Conformal. Rectum / radiation effects. Seminal Vesicles / radiation effects. Urinary Bladder / radiation effects

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Strahlenther Onkol. 2009 Nov;185(11):722-3 [19899004.001]
  • [Cites] J Urol. 2001 Sep;166(3):876-81 [11490237.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1424-30 [17544601.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1099-105 [17336216.001]
  • [Cites] Cancer J. 2003 Jul-Aug;9(4):268-76 [12967137.001]
  • [Cites] Strahlenther Onkol. 2008 Dec;184(12 ):668-73 [19107348.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):518-26 [16242256.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):943-55 [12605972.001]
  • [Cites] Radiother Oncol. 2006 Jul;80(1):78-81 [16828910.001]
  • [Cites] Strahlenther Onkol. 2007 Nov;183(11):610-6 [17960336.001]
  • [Cites] Strahlenther Onkol. 2007 Dec;183 Spec No 2:14-5 [18166999.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 1;72 (3):770-6 [18375075.001]
  • [Cites] Radiother Oncol. 2003 Nov;69(2):161-8 [14643953.001]
  • [Cites] Strahlenther Onkol. 2007 Jun;183(6):321-6 [17520186.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1084-9 [17606331.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):534-43 [16246497.001]
  • [Cites] Strahlenther Onkol. 2007 Feb;183(2):57-62 [17294108.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):6-13 [11777617.001]
  • [Cites] Strahlenther Onkol. 2008 Dec;184(12 ):674-8 [19107349.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6 [7713792.001]
  • [Cites] Radiat Oncol. 2007 Aug 08;2:29 [17686162.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):988-93 [11704322.001]
  • (PMID = 19899003.001).
  • [ISSN] 1439-099X
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


12. Schuurman JP, de Vries Reilingh TS, Roothaan SM, Bijleveld RT, Wiezer MJ: Urinary bladder metastasis from an esophageal adenocarcinoma: a case report. Am J Gastroenterol; 2009 Jun;104(6):1603-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary bladder metastasis from an esophageal adenocarcinoma: a case report.
  • [MeSH-major] Adenocarcinoma / secondary. Esophageal Neoplasms / pathology. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Diagnosis, Differential. Endoscopy, Gastrointestinal. Follow-Up Studies. Humans. Immunohistochemistry. Keratin-7 / analysis. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19491880.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-7
  •  go-up   go-down


13. Girgin C, Oder M, Sahin MO, Sezer A, Berkmen S, Aydin R, Dincel C: Erection- and ejaculation-preserving cystectomy with orthotopic urinary diversion: is it feasible? J Androl; 2006 Mar-Apr;27(2):263-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erection- and ejaculation-preserving cystectomy with orthotopic urinary diversion: is it feasible?
  • Of the cases, 3 patients had pT1 G3 transitional cell carcinoma (TCC) refractory to treatment and one had pT2a adenocarcinoma of the bladder.
  • Extirpation of the bladder and anterior proximal prostate en bloc with preservation of the vasa deferentia, seminal vesicles, posterior prostate, and neurovascular bundles was performed after pelvic lymphadenectomy.
  • [MeSH-major] Cystectomy / adverse effects. Ejaculation / physiology. Fertility / physiology. Penile Erection / physiology. Urinary Diversion / methods
  • [MeSH-minor] Adult. Female. Humans. Male. Urinary Incontinence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304209.001).
  • [ISSN] 0196-3635
  • [Journal-full-title] Journal of andrology
  • [ISO-abbreviation] J. Androl.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Kaouk JH, Goel RK, White MA, White WM, Autorino R, Haber GP, Campbell SC: Laparoendoscopic single-site radical cystectomy and pelvic lymph node dissection: initial experience and 2-year follow-up. Urology; 2010 Oct;76(4):857-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The development of laparoendoscopic single-site surgery and its application to urothelial malignancy has not been previously evaluated.
  • All patients underwent extracorporeal urinary diversion by way of extension of the umbilical port site.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy / methods. Endoscopy / methods. Laparoscopy / methods. Lymph Node Excision / methods. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Aged, 80 and over. Equipment Design. Feasibility Studies. Female. Follow-Up Studies. Humans. Laparoscopes. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery. Pelvis. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery. Urinary Diversion

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20646750.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Adeniran AJ, Tamboli P: Clear cell adenocarcinoma of the urinary bladder: a short review. Arch Pathol Lab Med; 2009 Jun;133(6):987-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of the urinary bladder: a short review.
  • In this short review, we discuss clear cell adenocarcinoma of the urinary bladder, a rare tumor that primarily affects women.
  • Clear cell adenocarcinoma consists of cells with abundant clear cytoplasm, arranged in solid, glandular, or tubulocystic patterns.
  • [MeSH-major] Adenocarcinoma, Clear Cell. Urinary Bladder Neoplasms
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19492895.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


16. Raabe NK, Lilleby W, Tafjord G, Aström L: [High dose rate brachytherapy in prostate cancer in Norway]. Tidsskr Nor Laegeforen; 2008 May 29;128(11):1275-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High dose rate brachytherapy in prostate cancer in Norway].
  • Brachytherapy with a high dose rate permits an escalation of dose within the prostate without increasing the risk of side effects to the surrounding rectum and bladder.
  • This article presents a study of the first 100 patients in Norway with localized/locally advanced prostate cancer treated with high dose-rate brachytherapy combined with external radiotherapy.
  • High dose rate brachytherapy is indicated in patients with prostate cancer of an intermediate or high risk or if a radiation dose with a full external beam proposes a hazard to the patient.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Prostatic Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18511969.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


17. Kim TH, Kim DY, Cho KH, Kim YH, Jung KH, Ahn JB, Chang HJ, Kim JY, Choi HS, Lim SB, Sohn DK, Jeong SY: Comparative analysis of the effects of belly board and bladder distension in postoperative radiotherapy of rectal cancer patients. Strahlenther Onkol; 2005 Sep;181(9):601-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of the effects of belly board and bladder distension in postoperative radiotherapy of rectal cancer patients.
  • PURPOSE: To compare the effect of reducing the irradiated small-bowel volume with the use of belly board, bladder distension or both methods combined, in patients with rectal cancer undergoing postoperative pelvic radiotherapy.
  • PATIENTS AND METHODS: This study enrolled 20 consecutive patients with rectal cancer who were scheduled to receive postoperative pelvic radiotherapy.
  • All patients underwent four sets of CT scans under four different methods as follows: group I: empty bladder without the use of a belly board; group II: empty bladder with the use of a belly board; group III: bladder distension without the use of a belly board; group IV: bladder distension with the use of a belly board.
  • CONCLUSION: Bladder distension was a more effective method than the belly board for reducing the irradiated small-bowel volume in postoperative pelvic radiotherapy of rectal cancer patients.
  • The combination of the belly board and bladder distension showed an additive effect and was the most effective method for reducing the irradiated small-bowel volume.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Intestine, Small / radiation effects. Radiotherapy Planning, Computer-Assisted. Rectal Neoplasms / radiotherapy. Urinary Bladder

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16170488.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Shigehara K, Taya T, Hisazumi H: Primary adenocarcinoma in the bladder diverticulum. Scand J Urol Nephrol; 2008;42(5):481-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma in the bladder diverticulum.
  • Cystoscopy revealed a papillary tumor within the diverticulum of the bladder.
  • A transurethral resection was performed and histopathological examination revealed adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Diverticulum / pathology. Urinary Bladder Diseases / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy. Cystectomy. Cystoscopy. Diagnosis, Differential. Hematuria / etiology. Humans. Male. Tomography, X-Ray Computed. Urinary Bladder / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18792856.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


19. Shinohara T, Misawa K, Sano H, Okawa Y, Takada A: Pseudomyxoma peritonei due to mucinous cystadenocarcinoma in situ of the urachus presenting as an inguinal hernia. Int J Clin Oncol; 2006 Oct;11(5):416-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During herniorrhaphy, we found a large amount of gelatinous mucinous material in the indirect-hernia sac and made a diagnosis of pseudomyxoma peritonei on cytological grounds.
  • The urachal cyst and the dome of the urinary bladder were excised.
  • On histological examination, a unilocular cyst was found to consist of noninvasive mucinous adenocarcinoma.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / diagnosis. Hernia, Inguinal / etiology. Neoplasms, Multiple Primary. Peritoneal Neoplasms / diagnosis. Pseudomyxoma Peritonei / diagnosis. Urachus

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):727-31 [10622499.001]
  • [Cites] J Clin Pathol. 1998 Jun;51(6):483-4 [9771454.001]
  • [Cites] Nihon Gan Chiryo Gakkai Shi. 1989 Oct 20;24(10 ):2394-9 [2482319.001]
  • [Cites] J Surg Oncol. 2000 Dec;75(4):270-4 [11135270.001]
  • [Cites] Eur J Surg Oncol. 2001 Feb;27(1):54-8 [11237493.001]
  • [Cites] Pathol Int. 1997 Jul;47(7):502-5 [9234391.001]
  • [Cites] J Clin Pathol. 2003 Feb;56(2):152-3 [12560399.001]
  • [Cites] Acta Radiol. 2004 May;45(3):348-50 [15239434.001]
  • [Cites] Radiographics. 2001 Mar-Apr;21(2):451-61 [11259707.001]
  • [Cites] AJR Am J Roentgenol. 2003 Apr;180(4):1183-4 [12646487.001]
  • [Cites] Indian J Pathol Microbiol. 2001 Apr;44(2):151-2 [11883134.001]
  • [Cites] J Urol. 1984 Jan;131(1):1-8 [6361280.001]
  • [Cites] Cancer. 1990 Oct 1;66(7):1636-40 [2208015.001]
  • [Cites] Cancer. 1975 Nov;36(5):1834-7 [1192367.001]
  • [Cites] South Med J. 1971 Apr;64(4):497-8 [4324014.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1985 Dec;82(12):2979-82 [3831450.001]
  • (PMID = 17058142.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Lee W: Urachal adenocarcinoma metastatic to the ovaries resembling primary ovarian mucinous carcinoma: a case report with the immunohistochemical study. Int J Clin Exp Pathol; 2010;4(1):118-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urachal adenocarcinoma metastatic to the ovaries resembling primary ovarian mucinous carcinoma: a case report with the immunohistochemical study.
  • I report here on a case of urachal adenocarcinoma that metastasized to bilateral ovaries in a 72-year-old female.
  • The kidney CT revealed a solid mass with calcification in the bladder dome, which suggested urachal carcinoma.
  • Histologically, the tumor corresponded to mucinous adenocarcinoma and centered at the bladder wall with predominant invasion of the muscularis.
  • [MeSH-major] Adenocarcinoma / secondary. Ovarian Neoplasms / secondary
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Female. Humans. Immunohistochemistry. Kidney Neoplasms / radiography. Kidney Neoplasms / secondary. Palliative Care. Tomography, X-Ray Computed. Urinary Bladder Neoplasms / metabolism. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Urachal adenocarcinoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2009 May;33(5):659-68 [19252435.001]
  • [Cites] J Urol. 2008 Aug;180(2):720 [18554640.001]
  • [Cites] Urology. 2001 Sep;58(3):462 [11549502.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):281-92 [12604884.001]
  • [Cites] AJR Am J Roentgenol. 2003 Apr;180(4):1183-4 [12646487.001]
  • [Cites] Int J Gynecol Pathol. 2003 Apr;22(2):189-93 [12649676.001]
  • [Cites] J Urol. 1984 Jan;131(1):1-8 [6361280.001]
  • [Cites] Virchows Arch. 1995;426(5):529-32 [7633664.001]
  • [Cites] J Urol. 1997 Nov;158(5):1722-7 [9334587.001]
  • [Cites] Int J Gynecol Pathol. 2005 Jan;24(1):4-25 [15626914.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1130-9 [16931958.001]
  • [Cites] Mod Pathol. 2006 Nov;19(11):1421-8 [16980943.001]
  • [Cites] Cancer. 2007 Dec 1;110(11):2434-40 [17932892.001]
  • [Cites] Am J Surg Pathol. 2007 Dec;31(12):1788-99 [18043033.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jul;27(3):366-79 [18580314.001]
  • [Cites] Int J Gynecol Cancer. 2009 Dec;19(9):1539-41 [19955933.001]
  • (PMID = 21228934.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; Urachal cancer
  • [Other-IDs] NLM/ PMC3016110
  • [Keywords] NOTNLM ; Urachus / adenocarcinoma / metastasis / mucinous / ovarian neoplasm
  •  go-up   go-down


21. Thirion P, Kelly C, Salib O, Moriarty M, O'Reilly D, Griffin M, Armstrong J: A randomised comparison of two brachytherapy devices for the treatment of uterine cervical carcinoma. Radiother Oncol; 2005 Mar;74(3):247-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on two-dimensional planning and the ICRU-38 bladder and rectal reference points, an advantage for the shielded Henschke applicator was demonstrated.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / instrumentation. Carcinoma, Squamous Cell / radiotherapy. Uterine Cervical Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15763304.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Ireland
  •  go-up   go-down


22. Agrawal A, Agrawal CS, Kumar A, Tiwari A, Lakshmi R, Yadav R: Gall bladder carcinoma: stroke as first manifestation. Indian J Gastroenterol; 2006 Nov-Dec;25(6):316
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gall bladder carcinoma: stroke as first manifestation.
  • Clinical presentation of gall bladder carcinoma with distant metastasis is extremely rare.
  • Further workup revealed a gall bladder mass with liver nodules.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / secondary. Gallbladder Neoplasms / diagnosis. Stroke / etiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17264439.001).
  • [ISSN] 0254-8860
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


23. Ikushima H, Takegawa Y, Osaki K, Furutani S, Yamashita K, Kawanaka T, Kubo A, Kudoh T, Nishitani H: Radiation therapy for cervical cancer in the elderly. Gynecol Oncol; 2007 Nov;107(2):339-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy for cervical cancer in the elderly.
  • OBJECTIVE: To evaluate the long-term results of radical radiation therapy (RT) for cervical cancer in elderly patients.
  • METHODS: We reviewed the clinical records of 727 patients with cervical cancer who underwent radical RT at the Tokushima University Hospital and compared the treatment results of three age groups: </=64 years (younger group [YG], 337 patients), 65-74 years (young-old group [YOG], 258 patients), and >/=75 years (older group [OG], 132 patients).
  • RESULTS: At the last follow-up, 155 YG (46%), 77 YOG (30%), and 48 OG patients (36%) had died of cervical cancer; the median follow-up periods were 82, 87, and 68 months, respectively.
  • Differences between OG and the other groups were not significant.
  • Late radiation morbidity of grades 2-4 in the bladder and/or rectum occurred in 22% of YG, 31% of YOG, and 8% of OG patients.
  • CONCLUSIONS: RT was well tolerated in elderly patients, and age was not a significant prognostic factor.
  • In the management of cervical cancer, advanced age is not a contraindication to radical RT.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Radiation Injuries / etiology. Uterine Cervical Neoplasms / radiotherapy


24. Deshpande V, Chicano S, Finkelberg D, Selig MK, Mino-Kenudson M, Brugge WR, Colvin RB, Lauwers GY: Autoimmune pancreatitis: a systemic immune complex mediated disease. Am J Surg Pathol; 2006 Dec;30(12):1537-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A control cohort composed of pancreatic adenocarcinoma (n=19) and chronic pancreatitis-not otherwise specified (NOS) (n=14) was also evaluated.
  • Eleven pancreatic specimens, including 2 cases of chronic pancreatitis-NOS and 4 kidneys were evaluated ultrastructurally.
  • The pancreas, bile duct, gall bladder, salivary gland, kidney, and lung lesions were characterized by dense lymphoplasmacytic infiltrates with reactive fibroblasts and venulitis.
  • The AIP cases showed significantly more pancreatic IgG4 positive plasma cells than chronic pancreatitis-NOS or adenocarcinoma (P=0.001).
  • However, IgG4 positive cells were identified in 57.1% of chronic pancreatitis-NOS and 47.4% of ductal adenocarcinoma.
  • Documentation of increased numbers of tissue IgG4 positive plasma cells, although not an entirely specific marker for AIP, may provide ancillary evidence for the diagnosis of a IgG4-related systemic disease.

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Surg Pathol. 2007 Feb;31(2):328. Chiocca, Sonia [corrected to Chicano, Sonia]
  • (PMID = 17122509.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigen-Antibody Complex; 0 / Biomarkers; 0 / Immunoglobulin G
  •  go-up   go-down


26. Lee TK, Chuang ST, Netto GJ: Conventional prostatic adenocarcinoma arising in a multilocular prostatic cystadenoma. Pathol Int; 2010 May;60(5):413-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conventional prostatic adenocarcinoma arising in a multilocular prostatic cystadenoma.
  • Multilocular prostatic cystadenoma is a rare benign neoplasm located between the bladder and the rectum.
  • We report the first case of conventional prostatic adenocarcinoma involving a multilocular cystadenoma.
  • [MeSH-major] Adenocarcinoma / pathology. Cystadenoma / pathology. Neoplasms, Multiple Primary / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Cystadenocarcinoma / diagnosis. Diagnosis, Differential. Humans. Male. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518893.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


27. Allaparthi S, Ramanathan R, Balaji KC: Robotic partial cystectomy for bladder cancer: a single-institutional pilot study. J Endourol; 2010 Feb;24(2):223-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic partial cystectomy for bladder cancer: a single-institutional pilot study.
  • OBJECTIVE: Open partial cystectomy has been used as a curative option for select group of patients with bladder cancer.
  • In recent years, the da Vinci Surgical Robotic System is being increasingly used to perform complex urologic cancer surgeries.
  • We report first on a consecutive cohort of patients undergoing robotic partial cystectomy (RPC) for bladder cancer.
  • METHODS: Three consecutive patients underwent RPC, two with diagnosis of papillary neoplasm of bladder and one with urachal adenocarcinoma at our institution from July 2008 to January 2009.
  • Final pathology demonstrated high-grade carcinoma pT2bNxMx and pTaNxMx papillary urothelial carcinoma in two patients and invasive adenocarcinoma of the bladder pT3aNxMx in the remaining patient.
  • CONCLUSIONS: RPC is technically feasible using the da Vinci Surgical Robotic System in select patients with bladder cancer without disease recurrence in the short term.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20039797.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Abe T, Hayashi T, Nakayama J, Kishikawa H, Sekii K, Yoshioka T, Itatani H, Kojima Y, Takahara S: [A case of synchronous double primary cancers of prostate, and bladder in a hemodialysis patient: a case report]. Hinyokika Kiyo; 2005 Oct;51(10):689-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of synchronous double primary cancers of prostate, and bladder in a hemodialysis patient: a case report].
  • Cystoscopy revealed papillary tumors on the right lateral bladder wall.
  • Transurethral resection of bladder tumor (TUR-Bt) was performed and histopathological examination showed transitional cell carcinoma, G2, pTa.
  • The histologic diagnosis of the transrectal needle prostate biopsy specimen was moderately differentiated adenocarcinoma.
  • A case of synchronous double primary cancers, comprised of adenocarcinoma of the prostate and transitional cell carcinoma of the urinary blader in a hemodialysis patient has never been previously reported in the Japanese literature.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Transitional Cell / diagnosis. Neoplasms, Multiple Primary. Prostatic Neoplasms / diagnosis. Renal Dialysis. Urinary Bladder Neoplasms / diagnosis


29. Rieder JM, Parsons JK, Gearhart JP, Schoenberg M: Primary squamous cell carcinoma in unreconstructed exstrophic bladder. Urology; 2006 Jan;67(1):199
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary squamous cell carcinoma in unreconstructed exstrophic bladder.
  • Bladder exstrophy is associated with an increased incidence of primary adenocarcinoma of the bladder.
  • We report a rare case of squamous cell carcinoma occurring in the unreconstructed, exstrophic bladder of a 53-year-old woman treated with radical cystectomy and radiochemotherapy.
  • This case represents the oldest patient to present with squamous cell carcinoma of an unreconstructed exstrophic bladder.
  • We discuss the potential mechanisms of carcinogenesis in this patient, noting how they may potentially differ from those in a patient with a reconstructed bladder.
  • [MeSH-major] Bladder Exstrophy / complications. Carcinoma, Squamous Cell / complications. Urinary Bladder Neoplasms / complications

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16413365.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Sert B: Robotic port-site and pelvic recurrences after robot-assisted laparoscopic radical hysterectomy for a stage IB1 adenocarcinoma of the cervix with negative lymph nodes. Int J Med Robot; 2010 Jun;6(2):132-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic port-site and pelvic recurrences after robot-assisted laparoscopic radical hysterectomy for a stage IB1 adenocarcinoma of the cervix with negative lymph nodes.
  • BACKGROUND: Port-site metastasis (PSM) following minimally invasive surgery for gynaecological cancer has been recognized as a potential problem over the last two decades.
  • METHODS: A 60 year-old woman with stage Ib1 adenocarcinoma of the cervix was treated with radical hysterectomy, bilateral salpingo-oophorectomy and bilateral pelvic lymph node dissection, using robot-assisted laparoscopy.
  • RESULTS: Eighteen months after primary surgery, the patient developed a pelvic recurrence invading both the bladder mucosa and the parametrium.
  • CONCLUSION: This is the first case report emphasizing the risk of PSM and early pelvic recurrences in robot-assisted laparoscopic radical hysterectomy and bilateral pelvic lymph node dissection for an early-stage cervical adenocarcinoma patient with negative lymph nodes, histologically examined by immunohistochemical ultrastaging.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Hysterectomy / methods. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery


31. Funahashi Y, Kamihira O, Kasugai S, Kimura K, Fukatsu A, Matsuura O: [Triple cancer in the urinary system: a case report]. Hinyokika Kiyo; 2007 Nov;53(11):813-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Triple cancer in the urinary system: a case report].
  • Cystoscopy showed many papillary bladder tumors under 5 mm in size.
  • Our case should be called triple cancer because bladder cancer was thought to be daughter tumor of renal pelvic tumor.
  • This is, to our knowledge, the 11th case report that occurred in the urinary tact, and the first case that needed total resection of urinary tract.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Kidney Pelvis. Neoplasms, Multiple Primary. Prostatic Neoplasms / diagnosis. Urinary Bladder Neoplasms / diagnosis


32. Kuhar CG, Mesti T, Zakotnik B: Digital ischemic events related to gemcitabine: Report of two cases and a systematic review. Radiol Oncol; 2010 Dec;44(4):257-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 65-year-old man was given the first-line treatment with gemcitabine for the advanced adenocarcinoma of pancreas.
  • A 77-year-old man, ex-smoker, was administered a combination of gemcitabine and cisplatin as the first-line treatment for the locally advanced bladder cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2000 Sep;11(9):1191-4 [11061617.001]
  • [Cites] Mund Kiefer Gesichtschir. 2002 Sep;6(5):331-5 [12448236.001]
  • [Cites] J Rheumatol. 2003 Jun;30(6):1341-3 [12784412.001]
  • [Cites] Rheum Dis Clin North Am. 2003 May;29(2):293-313 [12841296.001]
  • [Cites] Eur J Cancer Care (Engl). 2010 May;19(3):408-9 [19490003.001]
  • [Cites] Clin Ter. 2003 May-Jun;154(3):207-10 [12910811.001]
  • [Cites] Anticancer Drugs. 2003 Nov;14(10):829-32 [14597878.001]
  • [Cites] Neoplasma. 2004;51(5):334-40 [15640936.001]
  • [Cites] J Mal Vasc. 2005 Feb;30(1):53-7 [15924070.001]
  • [Cites] Nephrol Dial Transplant. 2006 Nov;21(11):3038-45 [16968717.001]
  • [Cites] Pain Physician. 2008 Jan;11(1):91-6 [18196175.001]
  • [Cites] Expert Opin Drug Saf. 2008 Nov;7(6):703-16 [18983217.001]
  • (PMID = 22933925.001).
  • [ISSN] 1581-3207
  • [Journal-full-title] Radiology and oncology
  • [ISO-abbreviation] Radiol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovenia
  • [Other-IDs] NLM/ PMC3423709
  • [Keywords] NOTNLM ; chemotherapy / digital ischemic events / gemcitabine vascular toxicity
  •  go-up   go-down


33. de Vries RR, Visser O, Nieuwenhuijzen JA, Horenblas S, Members of the Urological Oncology Working Group of the Comprehensive Cancer Centre Amsterdam: Outcome of treatment of bladder cancer: a comparison between low-volume hospitals and an oncology centre. World J Urol; 2010 Aug;28(4):431-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of treatment of bladder cancer: a comparison between low-volume hospitals and an oncology centre.
  • METHODS: All primary bladder tumours diagnosed between 1989 and 2003 were selected from the Amsterdam Cancer Registry, a population-based cancer registry (population 3.0 million).
  • Although postoperative mortality at this centre decreased from 4.0% in 1989-1997 to 1.1% in 1998-2003, the latter percentage was not statistically significantly different from the other hospitals during 1998-2003 (OR 0.3; P = 0.09).
  • CONCLUSIONS: We observed a lower postoperative mortality rate in the oncology centre compared to the low-volume hospitals; however, this difference did not reach statistical significance.
  • [MeSH-major] Cancer Care Facilities / statistics & numerical data. Carcinoma, Transitional Cell / mortality. Cystectomy / mortality. Hospital Bed Capacity / statistics & numerical data. Urinary Bladder Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Netherlands / epidemiology. Outcome Assessment (Health Care) / statistics & numerical data. Postoperative Complications / mortality. Registries / statistics & numerical data. Risk Factors

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):640-5 [14713777.001]
  • [Cites] Urology. 2006 Jul;68(1):58-64 [16806414.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1128-37 [11948273.001]
  • [Cites] Urol Oncol. 2007 Jan-Feb;25(1):66-71 [17208142.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):135-9 [17592302.001]
  • [Cites] Ann Surg Oncol. 2007 May;14(5):1678-87 [17294070.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):781-8, discussion 788-90 [16327488.001]
  • [Cites] J Urol. 2008 Jul;180(1):128-34; discussion 134 [18485375.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):886-9; discussion 889-90 [16469572.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):690-6 [12586807.001]
  • [Cites] Curr Opin Urol. 2006 Sep;16(5):344-9 [16905980.001]
  • [Cites] J Urol. 2007 Oct;178(4 Pt 1):1418-21; discussion 1421-2 [17706712.001]
  • [Cites] Ann Surg. 2007 May;245(5):777-83 [17457171.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2006-12 [16648501.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):91-6 [17194909.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):36-43 [15912515.001]
  • [Cites] Int Urol Nephrol. 2004;36(3):353-8 [15783105.001]
  • [Cites] Int Braz J Urol. 2007 Nov-Dec;33(6):764-73; discussion 774-6 [18199344.001]
  • [Cites] Eur J Surg Oncol. 2006 Jun;32(5):548-52 [16569495.001]
  • [Cites] J Urol. 2007 Jun;177(6):2095-9; discussion 2099 [17509295.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2781-9 [15199091.001]
  • [Cites] J Urol. 2006 Aug;176(2):486-92; discussion 491-2 [16813874.001]
  • [Cites] J Urol. 2005 Oct;174(4 Pt 1):1385-9; discussion 1389 [16145443.001]
  • [Cites] Postgrad Med J. 2007 Aug;83(982):556-60 [17675551.001]
  • [Cites] Cancer. 2005 Sep 1;104(5):975-84 [16044400.001]
  • [Cites] Eur Urol. 2009 Jan;55(1):164-74 [18675501.001]
  • [Cites] J Urol. 2008 Jul;180(1):121-7 [18485392.001]
  • (PMID = 20130885.001).
  • [ISSN] 1433-8726
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


34. Hansel DE, Nadasdy T, Epstein JI: Fibromyxoid nephrogenic adenoma: a newly recognized variant mimicking mucinous adenocarcinoma. Am J Surg Pathol; 2007 Aug;31(8):1231-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibromyxoid nephrogenic adenoma: a newly recognized variant mimicking mucinous adenocarcinoma.
  • All 8 patients were elderly men who had a prior or concurrent history of acinar prostate cancer (n=4), combined acinar prostate and urothelial carcinoma (n=1), urothelial-type adenocarcinoma of the prostate (n=1), bladder urothelial carcinoma (n=1), or no prior reported prostatic or urothelial abnormalities (n=1).
  • Awareness of this entity and the use of ancillary techniques can aid in the diagnosis of this unusual form of nephrogenic adenoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenoma / pathology. Fibroma / pathology. Urologic Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Male. Middle Aged. Mucins / analysis. Neoplasms, Multiple Primary. Urothelium / chemistry. Urothelium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667548.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


35. Castillo CM, Ha CY, Gater DR, Grob BM, Klausner AP: Prophylactic radical cystectomy for the management of keratinizing squamous metaplasia of the bladder in a man with tetraplegia. J Spinal Cord Med; 2007;30(4):389-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylactic radical cystectomy for the management of keratinizing squamous metaplasia of the bladder in a man with tetraplegia.
  • BACKGROUND/OBJECTIVE: To report a case of keratinizing squamous metaplasia of the bladder treated with radical cystectomy.
  • METHODS: Keratinizing squamous metaplasia of the bladder is a rare entity that can result from chronic irritative stimuli involving the bladder.
  • A case report is presented describing the diagnosis and management of keratinizing squamous metaplasia of the bladder in a tetraplegic man with a chronic indwelling urinary catheter.
  • Final pathology revealed focal erosion and diffuse keratinizing squamous metaplasia of the bladder with prostatic adenocarcinoma as an incidental finding.
  • CONCLUSIONS: Patients with spinal cord injury who use indwelling catheters for bladder management are at higher risk of developing keratinizing squamous metaplasia.
  • An interdisciplinary approach is recommended before consideration of bladder resection.
  • [MeSH-major] Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / surgery. Cystectomy / methods. Quadriplegia / complications. Urinary Bladder Neoplasms / etiology. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Indian J Pathol Microbiol. 1994 Dec;37 Suppl:S39-40 [8613170.001]
  • [Cites] Arch Phys Med Rehabil. 1995 Aug;76(8):758-62 [7632132.001]
  • [Cites] J Urol. 1997 Jun;157(6):2115 [9146594.001]
  • [Cites] SCI Nurs. 1997 Sep;14(3):87-95 [9355615.001]
  • [Cites] J Clin Pathol. 1998 Aug;51(8):583-7 [9828815.001]
  • [Cites] Urology. 1999 Feb;53(2):292-7 [9933042.001]
  • [Cites] World J Urol. 1999 Aug;17(4):211-8 [10460403.001]
  • [Cites] Urol Clin North Am. 2005 May;32(2):207-16 [15862618.001]
  • [Cites] J Urol. 2005 Nov;174(5):1729-36 [16217273.001]
  • [Cites] Am J Surg Pathol. 2006 Jul;30(7):883-91 [16819332.001]
  • [Cites] Int Urol Nephrol. 1999;31(4):457-61 [10668940.001]
  • [Cites] Spinal Cord. 2001 Nov;39(11):568-70 [11641805.001]
  • [Cites] BJU Int. 2002 Sep;90(4):386-90 [12175394.001]
  • [Cites] Eur Urol. 2002 Oct;42(4):350-5 [12361900.001]
  • [Cites] Eur Urol. 2002 Nov;42(5):469-74 [12429156.001]
  • [Cites] J Spinal Cord Med. 2003 Winter;26(4):335-8 [14992333.001]
  • [Cites] Qual Life Res. 2004 Feb;13(1):97-110 [15058792.001]
  • [Cites] Rehabil Nurs. 2004 Jul-Aug;29(4):122-6 [15222093.001]
  • [Cites] J Urol. 1967 Aug;98(2):206-8 [6046997.001]
  • [Cites] Urology. 1975 Dec;6(6):759-61 [1202729.001]
  • [Cites] J Urol. 1977 Dec;118(6):967-71 [926277.001]
  • [Cites] J Urol. 1979 Sep;122(3):317-21 [470001.001]
  • [Cites] S Afr Med J. 1980 Nov 1;58(18):725-8 [7423317.001]
  • [Cites] J Urol. 1985 Jun;133(6):1034-5 [3999203.001]
  • [Cites] J Urol. 1997 Jun;157(6):2112-4 [9146593.001]
  • (PMID = 17853664.001).
  • [ISSN] 1079-0268
  • [Journal-full-title] The journal of spinal cord medicine
  • [ISO-abbreviation] J Spinal Cord Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2031939
  •  go-up   go-down


36. Trna J, Husová L, Oliverius M, Dastych M Jr, Senkyrík M, Príbramská V: [The case of familial adenomatous polyposis and a proposal for the system of dispensarisation]. Vnitr Lek; 2009 Jun;55(6):587-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The adenocarcinoma had been treated using all available oncology therapeutic modalities.
  • When the conservative methods, including enteral and, subsequently, home total parenteral nutrition, were unsuccessful, the patient underwent successful surgery with resection of the affected intestinal loops, part of the bladder, evacuation of an abscess in the small pelvis and terminal jejunostomy.
  • [MeSH-minor] Adenocarcinoma / surgery. Colonic Neoplasms / surgery. Digestive System Surgical Procedures / adverse effects. Female. Humans. Middle Aged. Short Bowel Syndrome / etiology. Short Bowel Syndrome / therapy

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19662891.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


37. Moreno Sierra J, Victor Romano S, Galante Romo I, Barrera Ortega J, Salinas Casado J, Silmi Moyano A: [New male sling "Argus" for the treatment of stress urinary incontinence]. Arch Esp Urol; 2006 Jul-Aug;59(6):607-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New male sling "Argus" for the treatment of stress urinary incontinence].
  • [Transliterated title] Nuevo sling masculino "Argus" para el tratamiento de la incontinencia urinaria de esfuerzo.
  • OBJECTIVES: Male stress urinary incontinence is usually a consequence or sequel of a prostatic surgical procedure (radical prostatectomy, surgery for BPH or bladder neck sclerosis: adenomectomy, conventional and/or bipolar transurethral resection, laser...).
  • This kind of surgery may have undesirable effects on the quality of life and patients' expectations, although we should bear in mind that the primary objective in patients with prostate adenocarcinoma is to cure cancer and for patients with obstructive lower urinary tract symptoms to improve their voiding quality Over the last decade, surgical procedures to compress the bulbar urethra with slings have been employed successfully in the treatment of male stress urinary incontinence, being considered highly effective in the treatment of post-prostatectomy incontinence in the long-term by groups with large experience.
  • 3. This article does not intend to show our short experience with only five cases, but we want to mention that all of them are continent with a good quality of life.
  • [MeSH-major] Prostheses and Implants. Urinary Incontinence, Stress / surgery

  • Genetic Alliance. consumer health - Incontinence.
  • MedlinePlus Health Information. consumer health - Pelvic Support Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933489.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


38. Mazzucchelli R, Barbisan F, Santinelli A, Scarpelli M, Galosi AB, Lopez-Beltran A, Cheng L, Kirkali Z, Montironi R: Prediction of prostatic involvement by urothelial carcinoma in radical cystoprostatectomy for bladder cancer. Urology; 2009 Aug;74(2):385-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of prostatic involvement by urothelial carcinoma in radical cystoprostatectomy for bladder cancer.
  • OBJECTIVES: To ascertain which variables of bladder urothelial carcinoma (UC) might be useful in predicting either UC involving the prostate (UCP) or incidental prostate adenocarcinoma in radical cystoprostatectomy specimens.
  • METHODS: The bladder and whole-mount prostate sections of 248 radical cystoprostatectomy specimens were reviewed.
  • Stepwise discriminant analysis was used to predict UCP or incidental prostate adenocarcinoma.
  • UC originated from the prostatic urethra and periurethral ducts in 78 (31.45%), and isolated direct extension of UC from the bladder was present in 16 patients (6.45%).
  • The periurethral ducts coexisted with direct extension of bladder UC in 11 patients (4.4%).
  • Prostate adenocarcinoma was identified in 123 patients (49.6%).
  • The tumor was in the trigone and bladder neck in 160 patients (64.5%).
  • Stepwise discriminant analysis selected 3 variables of bladder UC (previous recurrence and location and number of foci) and correctly predicted the group in 72.2% of patients without and with UCP.
  • Discriminant analysis selected 2 variables of bladder UC (focality and previous recurrence) and correctly predicted the group in 57.7% of patients without and with prostate adenocarcinoma.
  • CONCLUSIONS: Our approach can identify bladder UC variables that could guide urologists in the selection of the most appropriate surgical procedure.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy. Prostatectomy. Prostatic Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasms, Multiple Primary / diagnosis


39. Kobayashi S, Tsukamoto T, Tohsaka A, Tohma T: [A case of adenocarcinoma of the urinary bladder arising 45 years after ileal replacement of ureter for tuberculous ureteral stricture]. Hinyokika Kiyo; 2008 Mar;54(3):235-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of adenocarcinoma of the urinary bladder arising 45 years after ileal replacement of ureter for tuberculous ureteral stricture].
  • We report a case of adenocarcinoma arising in the urinary bladder 45 years after ileal replacement of ureter for tuberculous ureteral stricture.
  • Cystoscopic examination demonstrated a broadbased non-papillary tumor on the left posterior wall of the bladder and a papillary tumor at the anastomotic site between the bladder and ileal segment.
  • The histopathological examination demonstrated well differentiated adenocarcinoma of the bladder and ileal ureter.
  • Intestinal metaplasia widely infiltrated into the bladder epithelium around the anastomotic site.
  • [MeSH-major] Adenocarcinoma / etiology. Tuberculosis, Urogenital / surgery. Ureteral Obstruction / surgery. Urinary Bladder Neoplasms / etiology. Urinary Diversion

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18411782.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


40. Venizelos I, Tamiolakis D, Petrakis G: Primary combined carcinoid and adenocarcinoma of the ileum associated with transitional carcinoma of the bladder. Single case report. Rev Esp Enferm Dig; 2007 Mar;99(3):145-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary combined carcinoid and adenocarcinoma of the ileum associated with transitional carcinoma of the bladder. Single case report.
  • Composite neoplasms, carcinoid and adenocarcinoma have been reported to occur in several parts of the body, including the stomach, ampulla of Vater, large bowel, lung, and urinary bladder.
  • Here we report a case of a 74-year-old male with a composite carcinoid-adenocarcinoma of the ileum associated with a transitional cell carcinoma of the bladder.
  • The microscopical examination of the composite tumor showed an admixture of typical carcinoid tumor and moderately a differentiated adenocarcinoma.
  • A review of the literature revealed that this is the first reported case of composite carcinoid-adenocarcinoma of the ileum associated with transitional cell carcinoma of the urinary bladder.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoid Tumor / pathology. Carcinoma, Transitional Cell / pathology. Ileal Neoplasms / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Rev Esp Enferm Dig. 2007 Nov;99(11):682. Venizelos, I D [corrected to Venizelos, I]; Lambropoulou, M [removed]; Constantinidis, T [removed]; Alexiadis, G [removed]; Papadopoulos, N [removed]
  • (PMID = 17516827.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


41. Petersen M, Meyer F, Kalinski T, Bischoff J, Bohr UR, Lippert H: [Rare neuroendocrine carcinoma of the gall bladder. Coincidental occurrence of an endometrioid ovarian adenocarcinoma]. Dtsch Med Wochenschr; 2009 Jan;134(1-2):19-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rare neuroendocrine carcinoma of the gall bladder. Coincidental occurrence of an endometrioid ovarian adenocarcinoma].
  • INVESTIGATIONS: Comparative immunochemistry, done to exclude metastatic growth of the previously demonstrated endometrioid ovarian carcinoma, was (1) negative for CK7 and CA125, positive for CK20, chromogranin A and synaptophysin (gall bladder and lymph node metastasis);.
  • DIAGNOSIS: The tumor lesion within the gall bladder and lymph node was classified as a neuroendocrine carcinoma, not a metastasis of the ovarian carcinoma.
  • TREATMENT AND CLINICAL COURSE: The patient underwent another laparotomy with resection of the stump of the cystic duct and the liver parenchyma surrounding the former gall bladder, including dissection of the lymph nodes within the hepatoduodenal ligament.
  • After 14 months another metastasis of the neuroendocrine carcinoma of the gall bladder was found.
  • But for eight years there has been no recurrence of the endometrioid adenocarcinoma of the left ovary.
  • This is the first case, according to the available literature, of an endometrioid adenocarcinoma of the ovary concomitant with a neuroendocrine carcinoma of the gall bladder.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Gallbladder Neoplasms / diagnosis. Neoplasms, Second Primary / diagnosis. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Dtsch Med Wochenschr. 2019 Sep;134(39):1915
  • (PMID = 19090447.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


42. Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients. Int Semin Surg Oncol; 2007 Sep 20;4:23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients.
  • BACKGROUND: although preoperative RT (Radiation Therapy) is becoming the preferred approach for combined treatment of locally advanced rectal adenocarcinoma, no regimen can be now considered as a standard.
  • METHODS: patients were screened following these eligibility criteria: histology-proven adenocarcinoma of the rectum; distal tumour extent at 12 cm or less from the anal verge; clinical stage T3-4/anyN, or anyT/N1-2; ECOG Performance Status 0-2.
  • Long-term complications included 1 case of radiation enteritis requiring surgery, 2 cases of anastomotic stricture and 3 cases of bladder incontinence.
  • CONCLUSION: bifractionated accelerated RT administered in the preoperative setting to patients bearing locally advanced rectal cancer is reliable and safe, as its immediate and late toxicity (mainly infectious) is acceptably low and long-term survivals are achievable.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1990 Feb;211(2):187-95 [2405793.001]
  • [Cites] Am J Surg. 1994 Jan;167(1):90-4; discussion 94-5 [8311145.001]
  • [Cites] Ann Surg. 1998 Feb;227(2):157-67 [9488510.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):388-96 [10699069.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):633-40 [11685026.001]
  • [Cites] Lancet. 2000 Jul 8;356(9224):93-6 [10963244.001]
  • [Cites] Ann Surg. 1994 Nov;220(5):676-82 [7979617.001]
  • [Cites] Br J Radiol. 1989 Aug;62(740):679-94 [2670032.001]
  • [Cites] Strahlenther Onkol. 2002 May;178(5):259-62 [12082685.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):964-8 [8813788.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):67-73 [7826163.001]
  • [Cites] Dis Colon Rectum. 1992 Aug;35(8):757-61 [1643999.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 May;10(5):593-8 [6735750.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):502-7 [8041415.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2396 [10561302.001]
  • [Cites] Strahlenther Onkol. 2004 Jan;180(1):5-14 [14704839.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):387-92 [1587760.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1291-304 [11684209.001]
  • [Cites] Clin Radiol. 1971 Apr;22(2):145-55 [5575251.001]
  • (PMID = 17883838.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2063497
  •  go-up   go-down


43. Castillo OA, Aranguibel JC, Sánchez-Salas R, Foneron A, Vitagliano G, Díaz M, Fajardo M: [Partial cystectomy. Our series]. Arch Esp Urol; 2007 Nov;60(9):1.111-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Partial cystectomy is a recognized bladder sparing surgical technique.
  • Partial cystectomy was indicated for the treatment of a foreign body, endometriosis, urachal adenocarcinoma, trancisional cell carcinoma, acquired lesions of urachus and extravesical tumor.
  • RESULTS: Nine patients with bladder lesions were laparoscopically operated for partial cystectomy.
  • It is a useful technique for both benign and malignant bladder disease.
  • [MeSH-major] Cystectomy / methods. Urinary Bladder Diseases / surgery

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18077866.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


44. Ryu HS, Park YL, Park SJ, Lee JH, Cho SB, Lee WS, Chung IJ, Kim KK, Lee KH, Kweon SS, Joo YE: KITENIN is associated with tumor progression in human gastric cancer. Anticancer Res; 2010 Sep;30(9):3479-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KITENIN is associated with tumor progression in human gastric cancer.
  • BACKGROUND: KAI1 COOH-terminal interacting tetraspanin (KITENIN) promotes tumor cell migration, invasion and metastasis in colon, bladder, head and neck cancer.
  • The aims of current study were to evaluate whether KITENIN affects tumor cell behavior in human gastric cancer cell line and to document the expression of KITENIN in a well-defined series of gastric tumors, including complete long-term follow-up, with special reference to patient prognosis.
  • MATERIALS AND METHODS: To evaluate the impact of KITENIN knockdown on behavior of a human gastric cancer cell line, AGS, migration, invasion and proliferation assays using small-interfering RNA were performed.
  • The expression of KITENIN and AP-1 target genes by RT-PCR and Western blotting or immunohistochemistry was also investigated in human gastric cancer tissues.
  • KITENIN expression was significantly increased in human cancer tissues at RNA and protein levels.
  • Expression of MMP-1, MMP-3, COX-2 and CD44 were significantly increased in human gastric cancer tissues.
  • Immunostaining of KITENIN was predominantly identified in the cytoplasm of cancer cells.
  • DISCUSSION: These results indicate that KITENIN plays an important role in human gastric cancer progression by AP-1 activation.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Carrier Proteins / metabolism. Membrane Proteins / metabolism. Stomach Neoplasms / pathology


45. Berberian JP, Goeman L, Allory Y, Abbou CC, Salomon L: Adenocarcinoma of ileal neobladder 20 years after cystectomy. Urology; 2006 Dec;68(6):1343.e9-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of ileal neobladder 20 years after cystectomy.
  • We present the case of a 67-year-old man with adenocarcinoma of the ileal neobladder 20 years after radical cystoprostatectomy for Stage pT2 transitional bladder cell cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Cystectomy / methods. Ileal Neoplasms / pathology. Urinary Diversion
  • [MeSH-minor] Aged. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Cystoscopy. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Reoperation. Time Factors. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17141834.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Mahmoudieh A, Tremblay C, Beaulieu L, Lachance B, Harel F, Lessard E, Pouliot J, Vigneault E: Anatomy-based inverse planning dose optimization in HDR prostate implant: a toxicity study. Radiother Oncol; 2005 Jun;75(3):318-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Between September 1999 and October 2002, 44 patients with locally advanced prostate cancer (PSA>/=10 ng/ml, and/or Gleason score>/=7, and/or Stage T2c or higher) were treated with 40-45 Gy external pelvic field followed by 2--3 fraction of inverse-planned HDR implant boost (6--9.5 Gy /fraction).
  • Dose-volume histograms for prostate, urethra, bladder, penis bulb and rectum were analyzed.
  • Acute (late) grade 2 urinary and rectal symptoms were reported in 31.8 (11.4%) and 4.6% (4.6%) of patients, respectively.
  • Erectile dysfunction occurs in approximately 27% of patients who were not on hormonal deprivation, but may be taking sildenafil.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Prostatic Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086913.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


47. Moore ML, Teitell MA, Kim Y, Watabe T, Reiter RE, Witte ON, Dubey P: Deletion of PSCA increases metastasis of TRAMP-induced prostate tumors without altering primary tumor formation. Prostate; 2008 Feb 1;68(2):139-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PSCA expression is upregulated in up to 70% of prostate tumors and metastases, and a subset of bladder and pancreatic cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Kidney Neoplasms / secondary. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Membrane Glycoproteins / metabolism. Neoplasm Proteins / metabolism. Prostatic Neoplasms / metabolism. Receptors, Tumor Necrosis Factor, Member 25 / metabolism

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - C57BL/6-Tg(TRAMP)8247Ng/J (subscription/membership/fee required).
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - STOCK Psca<tm1Witt>/J (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18044730.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA92131; United States / NCI NIH HHS / CA / R01CA107300; United States / NCI NIH HHS / CA / R01CA90571; United States / NCI NIH HHS / CA / U01 CA084128
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Birc5 protein, mouse; 0 / GPI-Linked Proteins; 0 / Inhibitor of Apoptosis Proteins; 0 / Membrane Glycoproteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Psca protein, mouse; 0 / Receptors, Tumor Necrosis Factor, Member 25; 0 / Repressor Proteins; 0 / Tnfrsf25 protein, mouse; EC 2.7.11.1 / Aurka protein, mouse; EC 2.7.11.1 / Aurkb protein, mouse; EC 2.7.11.1 / Aurora Kinase A; EC 2.7.11.1 / Aurora Kinase B; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


48. Kojima Y, Yamada Y, Kamisawa H, Sasaki S, Hayashi Y, Kohri K: Complete response of a recurrent advanced urachal carcinoma treated by S-1/cisplatin combination chemotherapy. Int J Urol; 2006 Aug;13(8):1123-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Urachus. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16903943.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


49. Puente S, Velasco A, Gallel P, Pallares J, Perez-Ruiz L, Ros S, Maravall J, Matias-Guiu X: Metastatic small cell carcinoma to the thyroid gland: a pathologic and molecular study demonstrating the origin in the urinary bladder. Endocr Pathol; 2008;19(3):190-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic small cell carcinoma to the thyroid gland: a pathologic and molecular study demonstrating the origin in the urinary bladder.
  • In some cases, demonstration of the primary tumor is not easy.
  • The primary tumor was a small cell carcinoma that occurred as a minor component in a transitional carcinoma of the urinary bladder.
  • The microscopical and immunohistochemical features of both tumors, in the thyroid and the bladder, were identical.
  • Moreover, both tumors exhibited an identical mutation in p53, as well as similar loss of heterozygosity at 10q23 and RASSF1A promoter hypermethylation, clearly indicating that the bladder tumor was the site for the primary tumor of the patient.
  • [MeSH-major] Carcinoma, Small Cell / genetics. Carcinoma, Small Cell / secondary. Thyroid Neoplasms / genetics. Thyroid Neoplasms / secondary. Urinary Bladder Neoplasms / genetics. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Base Sequence. Carcinoma, Transitional Cell / pathology. DNA Methylation. DNA Mutational Analysis. Humans. Immunohistochemistry. Loss of Heterozygosity. Male. Middle Aged. Neoplasms, Multiple Primary / pathology. Promoter Regions, Genetic / genetics. Prostatic Neoplasms / pathology. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1997 Jul;21(7):754-62 [9236831.001]
  • [Cites] Int J Oncol. 1999 Nov;15(5):927-34 [10536175.001]
  • [Cites] J Endocrinol Invest. 2005 Apr;28(4):371-8 [15966513.001]
  • [Cites] Am J Surg Pathol. 1980 Aug;4(4):333-41 [6999920.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(3):267-71 [2166978.001]
  • [Cites] Ann Intern Med. 1988 Sep 1;109(5):364-71 [2841895.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):718-23 [16084939.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1172-8 [15700264.001]
  • [Cites] Hum Pathol. 1989 Sep;20(9):896-902 [2550350.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jul;21(3):268-72 [12068173.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3B):2001-4 [16158936.001]
  • [Cites] Cancer. 2004 Sep 1;101(5):957-62 [15329903.001]
  • [Cites] Int J Exp Pathol. 2005 Aug;86(4):213-8 [16045543.001]
  • (PMID = 18446450.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RASSF1 protein, human; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


50. Izzo L, Pietrasanta D, Izzo P, Caputo M, Di Cello P, Meloni P, Bolognese A: A case of relapsing secondary bladder adenocarcinoma after right colonic cancer. Nat Clin Pract Urol; 2008 Jul;5(7):403-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of relapsing secondary bladder adenocarcinoma after right colonic cancer.
  • BACKGROUND: A 71-year-old woman was referred to a surgical oncology clinic after CT raised suspicion for a bladder neoplasm.
  • She had previously undergone right hemicolectomy and received adjuvant chemotherapy for pT3N1MX cancer of the cecum.
  • Follow-up CT raised suspicion for a possible bladder neoplasm.
  • DIAGNOSIS: Adenocarcinoma of the cecum metastatic to the bladder.
  • MANAGEMENT: The patient underwent open bladder resection with total excision of the neoplasm and was administered adjuvant chemotherapy consisting of irinotecan and cetuximab.
  • [MeSH-major] Adenocarcinoma / pathology. Cecal Neoplasms / pathology. Neoplasm Recurrence, Local / secondary. Urinary Bladder Neoplasms / secondary

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18604226.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Organoplatinum Compounds; 0 / Quinazolines; 0 / Thiophenes; 7673326042 / irinotecan; FCB9EGG971 / raltitrexed; PQX0D8J21J / Cetuximab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; Folfox protocol
  •  go-up   go-down


51. Liguori G, Amodeo A, Mucelli FP, Patel H, Marco D, Belgrano E, Trombetta C: Intractable haematuria: long-term results after selective embolization of the internal iliac arteries. BJU Int; 2010 Aug;106(4):500-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Between October 1997 and March 2009, 44 patients (30 men and 14 women; mean age 79 years, range 51-95) with intractable haematuria secondary to advanced pelvic tumour arising from or invading the bladder, underwent internal iliac TAE.
  • Twenty-four patients had transitional carcinoma of the urinary bladder, 12 adenocarcinoma of the prostate, five carcinoma of the uterus, one cancer of the vagina, two carcinoma of the rectum, three carcinoma of the kidney, two simultaneous carcinoma of prostate and bladder, one simultaneous carcinoma of prostate and kidney and one had haemorrhagic cystitis after radiotherapy.
  • [MeSH-major] Embolization, Therapeutic / methods. Hematuria / therapy. Iliac Artery. Pelvic Neoplasms / complications. Urinary Bladder Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20128777.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


52. Taranto AJ, Lourie R, Lau WF: Ovarian vascular pedicle sign in ovarian metastasis arising from gall bladder carcinoma. Australas Radiol; 2006 Oct;50(5):504-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian vascular pedicle sign in ovarian metastasis arising from gall bladder carcinoma.
  • A case of a large mass in the pelvis confirmed to be a rare ovarian metastasis arising from a primary adenocarcinoma of the gall bladder is presented.
  • [MeSH-major] Adenocarcinoma / pathology. Gallbladder Neoplasms / pathology. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / secondary. Ovary / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Contrast Media / administration & dosage. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Middle Aged. Positron-Emission Tomography / methods. Radiographic Image Enhancement / methods. Rare Diseases

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16981953.001).
  • [ISSN] 0004-8461
  • [Journal-full-title] Australasian radiology
  • [ISO-abbreviation] Australas Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Contrast Media; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


53. Constantinides C, Haritopoulos K, Anastasiou I, Dritsas C, Papamichael V, Zervas A: Multiple metastases of prostatic adenocarcinoma to the urethra after radical prostatectomy. Urol Int; 2007;79(1):92-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple metastases of prostatic adenocarcinoma to the urethra after radical prostatectomy.
  • We present a rare case of multiple metastases of a prostatic adenocarcinoma to the urethra.
  • Radical prostatectomy had been performed 13 years before, and during this time he had been frequently treated with transurethral resections of the bladder neck for obstructive urinary symptoms.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Prostatectomy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery. Urethral Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17627178.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


54. Mazzucchelli R, Barbisan F, Santinelli A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R: Immunohistochemical expression of prostate stem cell antigen in cystoprostatectomies with incidental prostate cancer. Int J Immunopathol Pharmacol; 2009 Jul-Sep;22(3):755-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of prostate stem cell antigen in cystoprostatectomies with incidental prostate cancer.
  • High expression of prostate stem cell antigen (PSCA) has been shown to be associated with adverse prognostic features in clinically-diagnosed prostate cancer.
  • PSCA expression was evaluated immunohistochemically in normal-looking epithelium (NEp), high-grade prostatic intraepithelial neoplasia (HGPIN) and pT2a Gleason score 6 acinar adenocarcinoma.
  • The evaluation was carried out on 20 cystoprostatectomies (CyPs) with incidental PCa from men with bladder urothelial carcinoma (UC), and 20 radical prostatectomies (RPs) with hormonally untreated PCa from men with clinically detected PCa.
  • In the CyPs the percentages of PSCA and Ki67 positive cells were lower than in the RPs, the differences between the CyP and RP compartments being not statistically significant.
  • However, there are no significant differences between CyPs with incidental prostate carcinoma and RPs with clinically diagnosed cancer.
  • [MeSH-major] Adenocarcinoma / immunology. Carcinoma, Acinar Cell / immunology. Immunohistochemistry. Incidental Findings. Membrane Glycoproteins / analysis. Neoplasm Proteins / analysis. Prostatic Intraepithelial Neoplasia / immunology. Prostatic Neoplasms / immunology. Urinary Bladder Neoplasms / immunology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19822092.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / GPI-Linked Proteins; 0 / Ki-67 Antigen; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / PSCA protein, human
  •  go-up   go-down


55. Kong CH, Singam P, Hong GE, Cheok LB, Azrif M, Tamil AM, Zainuddin ZM: Clinicopathological features of bladder tumours in a single institution in Malaysia. Asian Pac J Cancer Prev; 2010;11(1):149-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of bladder tumours in a single institution in Malaysia.
  • OBJECTIVE: To determine the clinicopathological features of bladder tumours encountered over a five year period in Universiti Kebangsaan Malaysia Medical Centre.
  • METHODS: Medical records of bladder tumour cases from 2005 till 2009 were retrospectively reviewed and tabulated.
  • The main histopathology was transitional cell carcinoma (TCC) (90.4%), followed by adenocarcinoma (6%), squamous cell carcinoma (1.2%), leiomyoma (1.2%) and myeloid sarcoma (1.2%).
  • Mean survival of patients with muscle invasive cancer was 33+/-5 months.
  • By the end of the study, 18.1% of patients had died of their cancer.
  • CONCLUSION: The incidence of bladder tumours is highest among the Chinese.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / secondary. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593947.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


56. Lum D: Clear cell carcinoma of the urinary bladder. Pathology; 2006 Aug;38(4):367-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the urinary bladder.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / pathology. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoembryonic Antigen / genetics. Carcinoembryonic Antigen / metabolism. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / genetics. Carcinoma, Transitional Cell / pathology. Diagnosis, Differential. Gene Expression Regulation, Neoplastic. Humans. Keratins / genetics. Keratins / metabolism. Male. Membrane Proteins / genetics. Membrane Proteins / metabolism. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16916733.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Carcinoembryonic Antigen; 0 / Membrane Proteins; 0 / Tumor Suppressor Protein p53; 68238-35-7 / Keratins
  •  go-up   go-down


57. Ramirez PT, Slomovitz BM, Soliman PT, Coleman RL, Levenback C: Total laparoscopic radical hysterectomy and lymphadenectomy: the M. D. Anderson Cancer Center experience. Gynecol Oncol; 2006 Aug;102(2):252-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total laparoscopic radical hysterectomy and lymphadenectomy: the M. D. Anderson Cancer Center experience.
  • Data collected included age, body mass index, stage, histopathologic subtype, tumor grade, estimated blood loss, perioperative blood transfusions, number and status of lymph nodes obtained, status of surgical margins, length of hospital stay, time to resumption of normal bladder function, intraoperative and postoperative complications, and disease-free interval.
  • Eighteen patients had cervix cancer (5 stage IA2 and 13 stage IB1), and 2 had endometrial cancer (1 stage IB and 1 stage IIIA).
  • Among those with cervix cancer, 12 had adenocarcinoma, 4 squamous cell carcinoma, and 2 adenosquamous carcinoma.
  • The median time to resumption of normal bladder function was 16 days (range, 13-29).
  • [MeSH-minor] Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / surgery. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2007 Feb;104(2):501; author reply 501-3 [17157902.001]
  • (PMID = 16472844.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A: Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol; 2005 Jul;206(3):356-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Overexpression of the tyrosine kinase receptor proteins was examined by immunohistochemistry in 221 biliary tract carcinomas, of which 28 were from the intrahepatic bile duct, 78 from the extrahepatic bile duct, 89 from the gall bladder, and 26 from the ampulla of Vater.
  • Overexpression of ErbB-2 was found in 15.7%, 11.5%, and 5.1% of carcinomas of the gall bladder, ampulla of Vater, and extrahepatic bile duct, respectively, and gene amplification was present in 79% of these.
  • Met overexpression, most frequent in intrahepatic bile duct carcinomas (21.4%), was not associated with gene amplification.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Ampulla of Vater / pathology. Bile Duct Neoplasms / genetics. Bile Duct Neoplasms / pathology. Bile Ducts, Extrahepatic / pathology. Bile Ducts, Intrahepatic / pathology. Common Bile Duct Neoplasms / genetics. Common Bile Duct Neoplasms / pathology. Female. Gallbladder Neoplasms / genetics. Gallbladder Neoplasms / pathology. Gene Amplification / genetics. Gene Expression Regulation, Neoplastic / genetics. Humans. Immunohistochemistry / methods. In Situ Hybridization, Fluorescence / methods. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Proteins / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 15892172.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-met; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


59. Hartmann A, Junker K, Dietmaier W, Schröder S, Lopez D, Hofstädter F, Blaszyk H: Molecular evidence for progression of nephrogenic metaplasia of the urinary bladder to clear cell adenocarcinoma. Hum Pathol; 2006 Jan;37(1):117-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular evidence for progression of nephrogenic metaplasia of the urinary bladder to clear cell adenocarcinoma.
  • Nephrogenic metaplasia or nephrogenic adenoma of the urinary tract may present a diagnostic challenge in surgical pathology practice.
  • Previous case reports suggest the possibility of nephrogenic metaplasia progressing to clear cell adenocarcinoma, but a malignant potential of nephrogenic metaplasia is generally not acknowledged.
  • A case of a 70-year-old female patient with multiple recurrences of nephrogenic metaplasia of the urinary bladder and subsequent development of clear cell adenocarcinoma is described.
  • Results of molecular studies, particularly comparative genomic hybridization analysis, suggest clonal evolution of nephrogenic metaplasia to clear cell adenocarcinoma in this case.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenoma / pathology. Precancerous Conditions / pathology. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16360424.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


60. Bango García V, Luján Marco S, Bosquet Sanz M, Gimeno Argente V, Arlandis Guzmán S, Alonso Gorrea M, Jiménez Cruz F: [Primary bladder adenocarcinoma in unreconstructed exstrophic bladder]. Actas Urol Esp; 2009 Feb;33(2):197-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary bladder adenocarcinoma in unreconstructed exstrophic bladder].
  • [Transliterated title] Adenocarcinoma vesical primario en extrofia vesical no corregida.
  • We report a 60-years-old patient with a not repaired exstrophic bladder, who develops an adenocarcinoma on his bladder and review of the literature.
  • [MeSH-major] Adenocarcinoma / complications. Bladder Exstrophy / complications. Urinary Bladder Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19418846.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


61. Lim M, Adsay NV, Grignon D, Osunkoya AO: Urothelial carcinoma with villoglandular differentiation: a study of 14 cases. Mod Pathol; 2009 Oct;22(10):1280-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors of the urinary bladder may have a variety of histological patterns.
  • However, urothelial carcinomas with both villous and glandular features have not been well characterized.
  • A concurrent high-grade papillary urothelial carcinoma component was identified in 11 cases (79%), micropapillary component in 5 (36%) cases, in-situ urothelial carcinoma component in 3 cases (21%), plasmacytoid component in 3 cases (21%), invasive adenocarcinoma in 2 cases, sarcomatoid carcinoma component in one case (14%), and small-cell carcinoma component in 1 case (7%).
  • [MeSH-major] Carcinoma / pathology. Cell Differentiation. Neoplasms, Glandular and Epithelial / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Aged, 80 and over. Biopsy. Carcinoma in Situ / pathology. Carcinoma, Small Cell / pathology. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Urothelium / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19593329.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Pushkar A, Khan L, Singh P, Agarwal A: Cutaneous metastasis from visceral malignancy: A rare presentation. J Cytol; 2009 Jul;26(3):109-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we report two cases of carcinoma gall bladder that presented with skin nodule.
  • Fine needle aspiration cytology of these nodules revealed metastatic deposits of adenocarcinoma and was instrumental in establishing the primaries.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] South Med J. 2003 Feb;96(2):164-7 [12630642.001]
  • [Cites] Am J Surg. 1961 Jul;102:90-3 [13777392.001]
  • [Cites] Int J Dermatol. 1995 May;34(5):360-2 [7607800.001]
  • [Cites] Arch Dermatol. 1972 Jun;105(6):862-8 [5030236.001]
  • [Cites] Ann Surg. 1950 Jul;132(1):121-8 [15426196.001]
  • (PMID = 21938168.001).
  • [ISSN] 0970-9371
  • [Journal-full-title] Journal of cytology
  • [ISO-abbreviation] J Cytol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3168011
  • [Keywords] NOTNLM ; Carcinoma gall bladder / cutaneous metastasis / periodic acid Schiff stain
  •  go-up   go-down


63. Lerner SP, Shen S: Pathologic assessment and clinical significance of prostatic involvement by transitional cell carcinoma and prostate cancer. Urol Oncol; 2008 Sep-Oct;26(5):481-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic assessment and clinical significance of prostatic involvement by transitional cell carcinoma and prostate cancer.
  • The prostate is commonly involved by transitional cell carcinoma (TCC) in patients with bladder cancer.
  • Distinct patterns and extent of pTCC have been described and are associated with pathologic stage of the primary bladder tumor as well as prognosis.
  • Given the high incidence of pTCC and prostatic adenocarcinoma, radical cystoprostatectomy is the treatment of choice for loco-regional control for patients with T4a disease.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Neoplasms, Multiple Primary / pathology. Prostatic Neoplasms / pathology. Urinary Bladder Neoplasms / pathology


64. Iqbal M, Gondal KM, Qureshi AU, Tayyab M: Comparative study of ultrasound guided fine needle aspiration cytology with open/laparoscopic biopsy for diagnosis of carcinoma gallbladder. J Coll Physicians Surg Pak; 2009 Jan;19(1):17-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative study of ultrasound guided fine needle aspiration cytology with open/laparoscopic biopsy for diagnosis of carcinoma gallbladder.
  • Smears showed adenocarcinoma 23, undifferentiated carcinoma in 7, dysplasia and suspicion of malignancy in 5, hemorrhagic background without malignant cells in 12 and inflammatory cells with no malignancy in 3 cases.
  • CONCLUSION: Ultrasound guided FNAC is a safe and less invasive diagnostic modality for diagnosing carcinoma gall bladder preventing the patient to undergo major surgery and helps in better quality of life.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Needle / methods. Gallbladder Neoplasms / pathology. Ultrasonography, Interventional / methods

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19149974.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


65. van de Bunt L, van der Heide UA, Ketelaars M, de Kort GA, Jürgenliemk-Schulz IM: Conventional, conformal, and intensity-modulated radiation therapy treatment planning of external beam radiotherapy for cervical cancer: The impact of tumor regression. Int J Radiat Oncol Biol Phys; 2006 Jan 1;64(1):189-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conventional, conformal, and intensity-modulated radiation therapy treatment planning of external beam radiotherapy for cervical cancer: The impact of tumor regression.
  • METHODS AND MATERIALS: Fourteen patients with cervical cancer underwent magnetic resonance (MR) imaging before treatment and once during treatment, after about 30 Gy.
  • RESULTS: The average volume receiving 95% of the prescribed dose (43 Gy) by the conventional, conformal, and IMRT plans was, respectively, for the bowel 626 cc, 427 cc, and 232 cc; for the rectum 101 cc, 90 cc, and 60 cc; and for the bladder 89 cc, 70 cc, and 58 cc.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Female. Humans. Magnetic Resonance Imaging. Radiation Injuries / prevention & control. Radiotherapy Dosage. Radiotherapy, Conformal. Radiotherapy, Intensity-Modulated. Rectum / radiation effects. Remission Induction. Urinary Bladder / radiation effects


66. Pantanowitz L, Otis CN: Cystitis glandularis. Diagn Cytopathol; 2008 Mar;36(3):181-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The differential diagnosis ranges from benign conditions such as cystitis glandularis to adenocarcinoma.
  • [MeSH-major] Cystitis / pathology. Urinary Bladder / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Choristoma / diagnosis. Cytodiagnosis. Diagnosis, Differential. Endometriosis / diagnosis. Female. Humans. Metaplasia. Urinalysis. Urinary Bladder Fistula / diagnosis. Urinary Bladder Neoplasms / diagnosis. Urine / cytology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18232007.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Tao Y, Lefkopoulos D, Ibrahima D, Bridier A, Polizzi Mdel P, Wibault P, De Crevoisier R, Arriagada R, Bourhis J: Comparison of dose contribution to normal pelvic tissues among conventional, conformal and intensity-modulated radiotherapy techniques in prostate cancer. Acta Oncol; 2008;47(3):442-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of dose contribution to normal pelvic tissues among conventional, conformal and intensity-modulated radiotherapy techniques in prostate cancer.
  • High-energy external radiotherapy has become one of the most common treatment in localized prostate cancer.
  • We compared the difference of dose distribution, mainly at the 5-30 Gy dose level, in the irradiated pelvic volume among three modalities of radiotherapy for patients with prostate cancer: conventional, conformal and intensity-modulated radiotherapy (IMRT).
  • We selected six patients with prostate cancer treated by conformal radiotherapy at the doses of 46 Gy to PTVN (prostate and seminal vesicles), and 70 Gy to PTV-T (prostate).
  • However, IMRT significantly reduced the irradiated volume of the rectum in the dose range of 5 to 40 Gy, also significantly reduced the irradiated volume of bladder and femoral heads, and obtained a similar or improved isodose distribution in the PTvs. In addition, the use of IMRT slightly increased the relative dose delivered to the body volume outside the pelvis, as estimated by the use of specific software.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Pelvis / radiation effects. Prostatic Neoplasms / radiotherapy. Radiotherapy Dosage. Radiotherapy, Conformal. Radiotherapy, Intensity-Modulated
  • [MeSH-minor] Dose-Response Relationship, Radiation. Femur Head / radiation effects. Humans. Male. Prostate / radiation effects. Radiation Injuries / prevention & control. Rectum / radiation effects. Seminal Vesicles / radiation effects. Urinary Bladder / radiation effects

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17906985.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


68. Raspollini MR, Comin CE, Crisci A, Chilosi M: The use of placental S100 (S100P), GATA3 and napsin A in the differential diagnosis of primary adenocarcinoma of the bladder and bladder metastasis from adenocarcinoma of the lung. Pathologica; 2010 Feb;102(1):33-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of placental S100 (S100P), GATA3 and napsin A in the differential diagnosis of primary adenocarcinoma of the bladder and bladder metastasis from adenocarcinoma of the lung.
  • Primary bladder adenocarcinoma accounts for 0.5-2% of all malignant bladder tumours.
  • Literature data indicate the bladder as the second most common site of metastatic genitourinary tumours, with the kidney as the most frequent location.
  • Secondary tumours of the bladder account for about 2.3% of all bladder malignancies encountered in surgical specimens.
  • Herein, we describe an adenocarcinoma deeply infiltrating the bladder wall, with no morphologic features of transitional cell carcinoma, in a patient with a previous diagnosis of primary lung adenocarcinoma, mixed subtype.
  • In this case, the use of a limited immunohistochemical panel including napsin A, a recently described highly sensitive marker for lung adenocarcinoma, GATA3 and S100P, two novel markers of urothelial differentiation, was of crucial importance in differentiating between lung adenocarcinoma metastatic to the bladder and primary bladder adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Aspartic Acid Endopeptidases / metabolism. Biomarkers, Tumor / metabolism. GATA3 Transcription Factor / metabolism. Lung Neoplasms. S100 Proteins / metabolism. Urinary Bladder Neoplasms

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20731252.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GATA3 Transcription Factor; 0 / GATA3 protein, human; 0 / S100 Proteins; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.- / NAPSA protein, human
  •  go-up   go-down


69. Soto Delgado M, Pedrero Márquez G, Varo Solís C, Rodríguez-Rubio Cortadellas FO, Sánchez Bernal C, González Moreno D: [Mucinous adenocarcinoma of the urachus and peritoneal pseudomyxoma]. Actas Urol Esp; 2006 Feb;30(2):222-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mucinous adenocarcinoma of the urachus and peritoneal pseudomyxoma].
  • [Transliterated title] Adenocarcinoma mucinoso de uraco y pseudomixoma peritoneal.
  • The adenocarcinoma of the urachus is very rare tumor, with an incidence of 1/5.000.000 inhabitants, represents less than 0.001 of all types of bladder cancer.
  • In this paper, we present a case of peritoneal pseudomixoma caused by a mucinous adenocarcinoma of the urachus.
  • [MeSH-major] Adenocarcinoma, Mucinous / complications. Pseudomyxoma Peritonei / etiology. Urachus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16700214.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


70. Ulla JL, Fernandez-Salgado E, Alvarez V, Ibañez A, Soto S, Carpio D, Vazquez-Sanluis J, Ledo L, Vazquez-Astray E: Pseudoachalasia of the cardia secondary to nongastrointestinal neoplasia. Dysphagia; 2008 Jun;23(2):122-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The origin of the neoplasm was bladder, prostate and metastases from epidermoid carcinoma of vocal chord.
  • Treatment of primary neoplasm, besides classical approach (with dilatation of botulinum injection) may help in the resolution of this clinical disorder.
  • [MeSH-major] Adenocarcinoma / complications. Botulinum Toxins, Type A / therapeutic use. Colonic Neoplasms / complications. Deglutition Disorders / diagnosis. Deglutition Disorders / etiology. Esophageal Achalasia. Neuromuscular Agents / therapeutic use. Urologic Neoplasms / complications
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Humans. Male. Paraneoplastic Syndromes

  • MedlinePlus Health Information. consumer health - Botox.
  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;423(6):507-11 [8291223.001]
  • [Cites] Am J Gastroenterol. 2001 Feb;96(2):373-9 [11232678.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):626-31 [11307099.001]
  • [Cites] Histopathology. 1999 Nov;35(5):445-53 [10583560.001]
  • [Cites] J Gastroenterol Hepatol. 1993 Nov-Dec;8(6):604-6 [8280848.001]
  • [Cites] Br Med J. 1947 Sep 13;2(4523):405-7 [20263258.001]
  • [Cites] Am J Gastroenterol. 1994 Nov;89(11):2014-8 [7942729.001]
  • [Cites] Gastroenterology. 1988 Nov;95(5):1279-86 [2844621.001]
  • [Cites] Am J Gastroenterol. 1995 Aug;90(8):1319-21 [7639237.001]
  • [Cites] Gastroenterology. 1996 Sep;111(3):648-54 [8780569.001]
  • [Cites] Am J Med. 1987 Mar;82(3):439-46 [3548347.001]
  • [Cites] Dig Dis Sci. 1980 Apr;25(4):311-3 [7389532.001]
  • [Cites] Ann Intern Med. 1978 Sep;89(3):315-8 [686541.001]
  • [Cites] Am J Gastroenterol. 1997 Apr;92 (4):624-8 [9128311.001]
  • [Cites] J Gastrointest Surg. 1999 Sep-Oct;3(5):456-61 [10482700.001]
  • [Cites] Am J Surg Pathol. 2000 Aug;24(8):1153-8 [10935657.001]
  • [Cites] Gastroenterology. 1991 Jan;100(1):137-42 [1845756.001]
  • [Cites] Endoscopy. 1990 Jan;22(1):1-4 [2407524.001]
  • [Cites] Ann Med Interne (Paris). 1993;144(4):303-4 [8368729.001]
  • [Cites] Gastroenterol Hepatol. 2000 Jan;23(1):14-5 [10726378.001]
  • [Cites] Dig Dis Sci. 1983 Mar;28(3):278-84 [6825547.001]
  • [Cites] Dysphagia. 1994 Spring;9(2):292-6 [8005010.001]
  • [Cites] J R Soc Med. 1988 Jul;81(7):399-402 [3045313.001]
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):784-8 [12023584.001]
  • [Cites] Scand J Gastroenterol. 2005 Apr;40(4):378-85 [16028431.001]
  • [Cites] Am J Gastroenterol. 1990 Oct;85(10):1327-30 [2220723.001]
  • [Cites] Neurology. 1998 Mar;50(3):652-7 [9521251.001]
  • [Cites] Am J Gastroenterol. 1998 Jan;93(1):103-5 [9448185.001]
  • (PMID = 17701248.001).
  • [ISSN] 0179-051X
  • [Journal-full-title] Dysphagia
  • [ISO-abbreviation] Dysphagia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neuromuscular Agents; EC 3.4.24.69 / Botulinum Toxins, Type A
  •  go-up   go-down


71. Ha YS, Kim YW, Min BD, Lee OJ, Kim YJ, Yun SJ, Lee SC, Kim WJ: Alpha-methylacyl-coenzyme a racemase-expressing urachal adenocarcinoma of the abdominal wall. Korean J Urol; 2010 Jul;51(7):498-500
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-methylacyl-coenzyme a racemase-expressing urachal adenocarcinoma of the abdominal wall.
  • To demonstrate the origin of the urachal adenocarcinoma is not easy, but it is very important for managing patient care.
  • Computed tomography revealed a well-defined enhancing mass with internal calcification and septation abutting on the dome of the urinary bladder.
  • The clinical diagnosis was urachal cancer, which seemed to invade the urinary bladder.
  • Thus, we performed mass excision and partial resection of the bladder.
  • To our knowledge, this report is the first case of AMACR-expressing urachal adenocarcinoma arising in the abdominal wall.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2005 Sep;18(9):1217-22 [15803184.001]
  • [Cites] Histopathology. 1998 Jan;32(1):20-7 [9522212.001]
  • [Cites] Eur J Surg Oncol. 1997 Apr;23(2):157-60 [9158192.001]
  • [Cites] J Urol. 1986 Jun;135(6):1240-4 [3712579.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1536-42 [17684125.001]
  • [Cites] Hum Pathol. 2003 Mar;34(3):228-33 [12673556.001]
  • [Cites] Radiographics. 2001 Mar-Apr;21(2):451-61 [11259707.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1677-82 [10749139.001]
  • [Cites] J Urol. 1984 Jan;131(1):1-8 [6361280.001]
  • (PMID = 20664785.001).
  • [ISSN] 2005-6745
  • [Journal-full-title] Korean journal of urology
  • [ISO-abbreviation] Korean J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2907501
  • [Keywords] NOTNLM ; Alpha-methylacyl-CoA racemase / Biological markers / Cystadenocarcinoma, mucinous / Urachus
  •  go-up   go-down


72. Sugita H, Egami H, Yokoyama Y, Suyama K, Ogawa M: Combined radical retropubic prostatectomy and abdominoperineal excision of the rectum for locally invasive rectal cancer as a less invasive surgery: report of a case. Int Surg; 2007 Sep-Oct;92(5):249-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined radical retropubic prostatectomy and abdominoperineal excision of the rectum for locally invasive rectal cancer as a less invasive surgery: report of a case.
  • The optimal therapy for carcinoma of the rectum with invasion of the prostate gland has not been established.
  • For a patient who has rectal carcinoma invading into the prostate and seminal vesicles and not invading into any other pelvic viscera, we performed combined radical retropubic prostatectomy and abdominoperineal excision of the rectum with reconstruction of the urinary tract by anastomosis of the ureter to the bladder.
  • After the operation, the patient had an infection of the abdominal wound and leakage of the anastomosis of the urethra to the bladder.
  • This technique obviates the need for urinary diversion or urinary reconstruction such as the neobladder in the case of total pelvic exenteration.
  • We consider this procedure is of benefit for improving the quality of life of patients with rectal cancer invading into the prostate.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy. Prostatectomy. Prostatic Neoplasms / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Aged. Anastomosis, Surgical. Humans. Male. Neoplasm Invasiveness. Rectum / surgery. Seminal Vesicles / pathology. Seminal Vesicles / surgery. Urethra / surgery. Urinary Bladder / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18399094.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


73. Sakamoto K, Watanabe M, De La Cruz C, Honda H, Ise H, Mitsui K, Namiki K, Mikami Y, Moriya T, Sasano H: Primary invasive micropapillary carcinoma of the colon. Histopathology; 2005 Nov;47(5):479-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IMPC has been reported in breast, urinary bladder, ureter, lung and parotid gland but not in colon.
  • One of the tumours (case 1) was nearly completely composed of IMPC, but the other two were associated with foci of adenocarcinoma and concurrent mucinous carcinoma, respectively.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16241995.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Mucin-1
  •  go-up   go-down


74. Zebentout O, Apardian R, Beaulieu L, Harel F, Martin AG, Vigneault E: [Clinical outcome of intermediate risk prostate cancer treated with iodine 125 monotherapy: The Hotel-Dieu of Quebec experience]. Cancer Radiother; 2010 Jun;14(3):183-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical outcome of intermediate risk prostate cancer treated with iodine 125 monotherapy: The Hotel-Dieu of Quebec experience].
  • [Transliterated title] Evolution clinique des patients atteints d'un cancer prostatique de risque intermédiaire traités par implants permanents d'iode-125 : l'expérience de l'Hôtel-Dieu de Québec.
  • PURPOSE: To describe the biochemical failure-free survival (BFFS), GU toxicity and erectile dysfunction in intermediate risk prostate cancer treated with iodine 125 monotherapy (I125).
  • PATIENTS AND METHODS: Between October 1994 and October 2007, 1282 patients were treated with I125 at the Hotel Dieu de Quebec.
  • Two hundred patients were intermediate risk prostate cancer.
  • Acute and late GU toxicity was described using the International Prostate Symptoms Score (IPSS) as well as with the rate of bladder catheter.
  • Acute urinary retention with bladder catheter occurred in 10.9% of patients.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy. Iodine Radioisotopes / therapeutic use. Prostatic Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.
  • (PMID = 20418145.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Iodine Radioisotopes; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


75. de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, Feuth T, Swinkels DW, Span PN: Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest; 2005 Jan;85(1):154-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression patterns of 13 frequently used housekeeping genes were determined in 80 normal and tumor samples from colorectal, breast, prostate, skin, and bladder tissues with real-time quantitative RT-PCR.
  • We recommend this gene for future studies to standardize gene expression measurements in cancer research and tumor diagnostics until a definite gold standard has been determined.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Female. Humans. Hypoxanthine Phosphoribosyltransferase / genetics. Hypoxanthine Phosphoribosyltransferase / metabolism. Male. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Principal Component Analysis. RNA, Messenger / metabolism. Reference Standards

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15543203.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 2.4.2.8 / Hypoxanthine Phosphoribosyltransferase
  •  go-up   go-down


76. Hoffmann MJ, Müller M, Engers R, Schulz WA: Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies. Biochem Pharmacol; 2006 Nov 30;72(11):1577-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aberrant hypomethylation in many cancers reactivates retrotransposons and selected single-copy genes such as cancer-testis antigens.
  • In prostate and bladder carcinoma cell lines and cancer tissues expression remained largely unchanged, but individual prostate carcinomas showed modestly increased CTCFL expression compared to normal tissues.
  • OCT4 expression was significantly decreased in cancer tissues.
  • CTCFL, but not OCT4 was dramatically induced in cancer cell lines by 5-aza-2'-deoxycytidine, but neither gene by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
  • Thus, CTCFL and OCT4 resemble cancer-testis antigens in being selectively hypomethylated and expressed in male germ cells but differ in lacking significant reexpression and hypomethylation in prostate carcinomas.
  • These findings imply that inhibitors of DNA methylation used for cancer treatment may induce CTCFL expression.
  • Teratocarcinoma cell lines showed nuclear, and 5-aza-2'-deoxycytidine-treated prostate cancer lines nuclear or cytoplasmatic localization.
  • [MeSH-major] Adenocarcinoma / genetics. DNA-Binding Proteins / genetics. Epigenesis, Genetic. Gene Expression Regulation, Neoplastic. Octamer Transcription Factor-3 / genetics. Testis. Urogenital Neoplasms / genetics. Zinc Fingers / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16854382.001).
  • [ISSN] 0006-2952
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTCFL protein, human; 0 / DNA-Binding Proteins; 0 / Octamer Transcription Factor-3; 0 / RNA, Messenger
  •  go-up   go-down


77. Kraft O: Incidental diagnosis of uterine cancer on 99mTc-dimercaptosuccinic acid renal scintigraphy. Hell J Nucl Med; 2005 May-Aug;8(2):132-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental diagnosis of uterine cancer on 99mTc-dimercaptosuccinic acid renal scintigraphy.
  • A large oval extrarenal uptake area above the urine bladder was also seen.
  • Histopathology showed a myomatous uterus with an adenocarcinoma which also affected both ovaria.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Kidney / radionuclide imaging. Pyelonephritis / radionuclide imaging. Radioisotope Renography / methods. Technetium Tc 99m Dimercaptosuccinic Acid. Uterine Neoplasms / radionuclide imaging

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hell J Nucl Med. 2005 Sep-Dec;8(3):176 [16390027.001]
  • (PMID = 16142257.001).
  • [ISSN] 1790-5427
  • [Journal-full-title] Hellenic journal of nuclear medicine
  • [ISO-abbreviation] Hell J Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 494JNQ8L28 / Technetium Tc 99m Dimercaptosuccinic Acid
  •  go-up   go-down


78. Mirabello L, Garcia-Closas M, Cawthon R, Lissowska J, Brinton LA, Pepłońska B, Sherman ME, Savage SA: Leukocyte telomere length in a population-based case-control study of ovarian cancer: a pilot study. Cancer Causes Control; 2010 Jan;21(1):77-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukocyte telomere length in a population-based case-control study of ovarian cancer: a pilot study.
  • Studies suggest that shorter telomeres in constitutional DNA are associated with bladder, breast, lung, and renal cancer.
  • Ovarian cancer tissues also have shortened telomeres and increased telomerase activity, suggesting that telomere abnormalities may be related to ovarian cancer.
  • METHODS: We investigated leukocyte telomere length in 99 women with serous ovarian adenocarcinoma and 100 age-matched cancer-free controls enrolled in a population-based case-control study.
  • CONCLUSIONS: This study shows that short leukocyte telomeres are associated with serous ovarian adenocarcinoma.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2000 Oct 31;159(2):175-81 [10996729.001]
  • [Cites] J Natl Cancer Inst. 1997 Jul 2;89(13):932-8 [9214672.001]
  • [Cites] Gynecol Oncol. 2002 Jan;84(1):81-4 [11748981.001]
  • [Cites] Science. 2002 Jul 26;297(5581):565-9 [12142527.001]
  • [Cites] J Int Med Res. 2002 May-Jun;30(3):244-50 [12166340.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 20;95(16):1211-8 [12928346.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Br J Haematol. 2004 Jul;126(1):63-71 [15198733.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1085-92 [9305709.001]
  • [Cites] Cell. 1997 Oct 3;91(1):25-34 [9335332.001]
  • [Cites] Int J Biochem Cell Biol. 2005 May;37(5):1000-13 [15743674.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:531-57 [16824017.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12(21):6345-50 [17085644.001]
  • [Cites] Neoplasia. 2007 Jan;9(1):81-9 [17325746.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):815-9 [17416776.001]
  • [Cites] BMC Cancer. 2007;7:60 [17411440.001]
  • [Cites] Front Biosci. 2007;12:4595-620 [17485399.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5538-44 [17545637.001]
  • [Cites] J Urol. 2007 Oct;178(4 Pt 1):1492-6 [17707063.001]
  • [Cites] Int J Gynecol Pathol. 2008 Apr;27(2):151-60 [18317228.001]
  • [Cites] Cancer Sci. 2008 Jul;99(7):1385-9 [18452563.001]
  • [Cites] Am J Epidemiol. 2009 Feb 1;169(3):323-9 [19056834.001]
  • [Cites] Nucleic Acids Res. 2009 Feb;37(3):e21 [19129229.001]
  • [Cites] Hepatology. 2004 Jul;40(1):80-6 [15239089.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):2900-4 [8159676.001]
  • [Cites] Nat Genet. 2001 Jun;28(2):155-9 [11381263.001]
  • (PMID = 19784860.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA082838; United States / Intramural NIH HHS / / Z01 CP010190-02; United States / NCI NIH HHS / CA / CA82838
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS301770; NLM/ PMC3130499
  •  go-up   go-down


79. Fosbrink M, Cudrici C, Niculescu F, Badea TC, David S, Shamsuddin A, Shin ML, Rus H: Overexpression of RGC-32 in colon cancer and other tumors. Exp Mol Pathol; 2005 Apr;78(2):116-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of RGC-32 in colon cancer and other tumors.
  • On the other hand, an increased RGC-32 protein was found in 70% of colon adenocarcinoma samples tested.
  • Overexpression of RGC-32 protein was found in other tumors including prostate, bladder, breast, lung, and other digestive tract tumors.
  • [MeSH-minor] Adenocarcinoma / metabolism. Blotting, Northern. Blotting, Western. Carcinoma / metabolism. Cell Line, Tumor. Humans. Immunohistochemistry. Immunoprecipitation. Ki-67 Antigen / metabolism. Polymerase Chain Reaction. RNA, Messenger / analysis. Up-Regulation

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15713436.001).
  • [ISSN] 0014-4800
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / ES 07263; United States / NINDS NIH HHS / NS / R01 NS42011
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Ki-67 Antigen; 0 / Muscle Proteins; 0 / Nerve Tissue Proteins; 0 / RGC32 protein, human; 0 / RNA, Messenger
  •  go-up   go-down


80. Langbein S, Zerilli M, Zur Hausen A, Staiger W, Rensch-Boschert K, Lukan N, Popa J, Ternullo MP, Steidler A, Weiss C, Grobholz R, Willeke F, Alken P, Stassi G, Schubert P, Coy JF: Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer; 2006 Feb 27;94(4):578-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted.
  • We have detected upregulation of a mutated transketolase transcript (TKTL1) in human malignancies, whereas transketolase (TKT) and transketolase-like-2 (TKTL2) transcripts were not upregulated.
  • As inhibition of transketolase enzyme reactions suppresses tumour growth and metastasis, TKTL1 could be the relevant target for novel anti-transketolase cancer therapies.
  • We suggest an individualised cancer therapy based on the determination of metabolic changes in tumours that might enable the targeted inhibition of invasion and metastasis.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / physiopathology. Colonic Neoplasms / genetics. Colonic Neoplasms / physiopathology. Gene Expression Profiling. Glycolysis. Transketolase / biosynthesis. Urinary Bladder Neoplasms / genetics


81. Soares MJ, Neves T, Covita A, Monteiro P, Canhoto A, Nogueira R, Barreto JL, Mendonça JC, Maya M, Monteiro H: [Bladder adenocarcinoma. Case report]. Arch Esp Urol; 2008 Sep;61(7):828-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder adenocarcinoma. Case report].
  • [Transliterated title] Adenocarcinoma vesical. Aportación de un caso clínico.
  • OBJECTIVE: Primary bladder adenocarcinoma is a rare entity.
  • METHOD/RESULTS: A 74 year old female patient presents to the emergency department with complaints of gross hematúria not accompanied by lower urinary tract symptoms.
  • Diagnostic work-up included renal and bladder ultrasound, cistoscopy and abdomino-pelvic C. T. scan.
  • Trans-urethral resection revealed an invasive adenocarcinoma.
  • The bladder specimen showed primary bladder adenocarcinoma, pT3aNO.
  • At 6 months of follow-up, the patient does not present disease progression or surgical complications.
  • CONCLUSION: Primary bladder adenocarcinoma is rare.
  • [MeSH-major] Adenocarcinoma. Urinary Bladder Neoplasms

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18972921.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 17
  •  go-up   go-down


82. Adams B, Sawhney R, Sheil A, Chaudhary UB: A rare case of clear cell adenocarcinoma of the bladder with unique pathological features. Am J Med Sci; 2007 Jan;333(1):63-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of clear cell adenocarcinoma of the bladder with unique pathological features.
  • Clear cell adenocarcinomas of the urinary bladder are rare tumors with an unknown histogenesis.
  • While specific criteria for a diagnosis of clear cell adenocarcinoma have not been defined, there are consistent staining patterns suggested for characterization.
  • We present an important case of clear cell adenocarcinoma of the bladder with a unique staining pattern.
  • We review the literature and discuss the differential diagnosis and various theories concerning the origin of this rare tumor.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17220697.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


83. Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P, Fogel M: Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum Pathol; 2006 Aug;37(8):1000-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy.
  • Nongynecological tumors expressing L1 comprised malignant melanoma, colon adenocarcinoma positive to chromogranin, clear-cell adenocarcinoma of the urinary bladder, pheochromocytoma, small cell lung carcinoma, and tumors of the nervous system.
  • Surprisingly, L1 expression in established breast and renal carcinoma cell lines was not a predictor for its presence in these human tumors in vivo.
  • Our results suggest that L1 expression in tumors is not ubiquitous but restricted to certain subtypes and may be a helpful molecular marker for differential diagnosis and target for antibody-based therapy.
  • [MeSH-minor] Antibodies, Monoclonal / immunology. Cell Line, Tumor. Diagnosis, Differential. Female. Fluorescent Antibody Technique, Direct. GPI-Linked Proteins. Humans. Immunoenzyme Techniques. Male. Neutrophils / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16867862.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CD177 protein, human; 0 / GPI-Linked Proteins; 0 / Isoantigens; 0 / Membrane Glycoproteins; 0 / Receptors, Cell Surface
  •  go-up   go-down


84. Jayram G, Katz MH, Steinberg GD: Radical cystectomy in patients previously treated for localized prostate cancer. Urology; 2010 Dec;76(6):1430-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical cystectomy in patients previously treated for localized prostate cancer.
  • OBJECTIVES: To present outcomes of a contemporary series of patients undergoing radical cystectomy (RC) for bladder cancer after previous treatment for localized cancer of the prostate (CaP).
  • METHODS: A retrospective review of more than 1000 RCs performed for bladder cancer between 1995 and 2008 identified 49 patients previously treated for localized CaP.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carcinoma, Transitional Cell / surgery. Cystectomy / methods. Neoplasms, Second Primary / surgery. Postoperative Complications / epidemiology. Prostatic Neoplasms / radiotherapy. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Brachytherapy / adverse effects. Carcinoma, Small Cell / etiology. Carcinoma, Small Cell / surgery. Humans. Male. Middle Aged. Neoplasms, Radiation-Induced / etiology. Neoplasms, Radiation-Induced / surgery. Prostatectomy. Radiation Injuries / complications. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, High-Energy / adverse effects. Risk. Treatment Outcome. Ureteral Obstruction / epidemiology. Ureteral Obstruction / etiology. Urinary Bladder / radiation effects. Urinary Bladder Neck Obstruction / epidemiology. Urinary Bladder Neck Obstruction / etiology. Urinary Diversion


85. Nese N, Kesici G, Lekili M, Isisag A: Urachal urothelial carcinoma diagnosed at a radical prostatectomy operation: a case report. Anal Quant Cytol Histol; 2010 Jun;32(3):174-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prostatic adenocarcinoma (PCa) (Gleason score 6) was diagnosed by needle biopsies.
  • After the diagnosis of high grade, muscle invasive UCa with intact mucosa on frozen examination of the dome of bladder wall during the radical prostatectomy operation (RPO), partial cystectomy was performed.
  • Six months after the diagnosis, an undifferentiated tumor was detected in a bladder transurethral resection specimen; thus, chemotherapy was given.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701072.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Keiler L, Dobbins D, Kulasekere R, Einstein D: Tomotherapy for prostate adenocarcinoma: a report on acute toxicity. Radiother Oncol; 2007 Aug;84(2):171-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tomotherapy for prostate adenocarcinoma: a report on acute toxicity.
  • BACKGROUND AND PURPOSE: To analyze the impact of Tomotherapy (TOMO) intensity modulated radiotherapy (IMRT) on acute gastrointestinal (GI) and genitourinary (GU) toxicity in prostate cancer.
  • In univariate analysis, androgen deprivation, prostate volume, pre-treatment urinary toxicity, and prostate dose homogeneity correlated with acute GI and GU toxicity.
  • With multivariate analysis use of Tomotherapy, median bladder dose and bladder dose homogeneity remained significantly correlated with GU toxicity.
  • CONCLUSIONS: Acute GI toxicity for prostate cancer is improved with Tomotherapy at a cost of increased acute GU toxicity possibly due to differences in bladder and prostate dose distribution.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Prostatic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / adverse effects
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Prostate / drug effects. Radiotherapy Dosage. Urinary Bladder / drug effects

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17692975.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


87. Hirata K, Kanemitsu S, Nakayama Y, Nagata N, Itoh H, Ohnishi H, Ishikawa H, Furukawa Y, HNPCC registry and genetic testing project of the Japanese Society for Cancer of the Colon and Rectum (JSCCR): A novel germline mutation of MSH2 in a hereditary nonpolyposis colorectal cancer patient with liposarcoma. Am J Gastroenterol; 2006 Jan;101(1):193-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel germline mutation of MSH2 in a hereditary nonpolyposis colorectal cancer patient with liposarcoma.
  • BACKGROUND: One of the clinical features of hereditary nonpolyposis colorectal cancer (HNPCC) is a high incidence of multiple primary neoplasms arising in various organs including the gastrointestinal and genitourinary tracts.
  • METHODS AND RESULTS: A 40-yr-old Japanese patient, who had a past history of adenocarcinoma of the rectum and transitional cell carcinoma of the urinary bladder, developed a liposarcoma in his left thigh.
  • Although his family history did not fulfill the revised Amsterdam criteria, his blood sample was subjected to genetic testing.
  • Direct sequencing of the genomic DNA from the blood identified an AT deletion at codon 677 in exon 13 of hMSH2, a pathogenic mutation that has not been reported before.
  • The expression of MSH2 in the liposarcoma and rectal cancer of the patient was analyzed by immunohistochemistry, which revealed loss of MSH2 expression in the tumors.
  • Since an immunohistochemical analysis showed no nuclear staining for MSH2 protein in the liposarcoma as well as the rectal cancer, the loss of wild-type MSH2 protein was thus considered to possibly play a role in the development of liposarcoma in HNPCC patients.
  • [MeSH-major] Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Liposarcoma / pathology. Muscle Neoplasms / pathology. MutS Homolog 2 Protein / genetics. Neoplasms, Multiple Primary / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Base Pair Mismatch. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / pathology. Follow-Up Studies. Germ-Line Mutation. Humans. Male. Risk Assessment


88. Lawton CA, Michalski J, El-Naqa I, Kuban D, Lee WR, Rosenthal SA, Zietman A, Sandler H, Shipley W, Ritter M, Valicenti R, Catton C, Roach M 3rd, Pisansky TM, Seider M: Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys; 2009 Jun 1;74(2):377-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2002 Jul 13;360(9327):103-6 [12126818.001]
  • [Cites] IEEE Trans Med Imaging. 2004 Jul;23(7):903-21 [15250643.001]
  • [Cites] Biometrics. 1977 Mar;33(1):159-74 [843571.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):1055-62 [9869229.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2497-504 [18413638.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):647-53 [17011443.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):646-55 [17531401.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):585-91 [18172188.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1285-90 [15817329.001]
  • (PMID = 18947941.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA081647-11; United States / NCI NIH HHS / CA / U24 CA081647; United States / NCI NIH HHS / CA / U24 CA081647-11; United States / NCI NIH HHS / CA / U24 CA81647
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS212882; NLM/ PMC2905162
  •  go-up   go-down


89. Peña González JA, González Sala JL, García Rojo D, Prera Vilaseca A, Hannaoui N, Vicente Palacio E, Abad Gairin C, Graells Batet A, Descalzo Abdad MC, Prats López J: [Extra peritoneal laparoscopic radical prostatectomy. Preliminary results]. Arch Esp Urol; 2005 Nov;58(9):937-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the last 6, only one was not completed by laparoscopy.
  • There were not major complications.
  • Not ileus was observed.
  • In one case, bladder catheter had to be replaced after 7 days because it was not properly placed during surgery.
  • Conversion to open surgery during extraperitoneal laparoscopic proceeding is not very difficult but previous surgical experience is required.
  • Initial learning curve has not caused any important complication.
  • [MeSH-major] Adenocarcinoma / surgery. Laparoscopy / methods. Prostatectomy / methods. Prostatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16430042.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


90. Flaig TW, La Rosa FG, McKinney K, Maroni P, Wilson S: A man with changes in the urinary bladder: benign metaplasia or adenocarcinoma? Oncology (Williston Park); 2009 Feb;23(2):177-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A man with changes in the urinary bladder: benign metaplasia or adenocarcinoma?
  • [MeSH-major] Adenocarcinoma / diagnosis. Cystitis / diagnosis. Kidney Neoplasms / diagnosis. Lymphatic Diseases / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Metaplasia. Nephrolithiasis / complications. Referral and Consultation

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19323300.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Bayley A, Rosewall T, Craig T, Bristow R, Chung P, Gospodarowicz M, Ménard C, Milosevic M, Warde P, Catton C: Clinical application of high-dose, image-guided intensity-modulated radiotherapy in high-risk prostate cancer. Int J Radiat Oncol Biol Phys; 2010 Jun 1;77(2):477-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical application of high-dose, image-guided intensity-modulated radiotherapy in high-risk prostate cancer.
  • METHODS AND MATERIALS: A total of 103 high-risk prostate cancer patients received two-phase, dose-escalated, image-guided IMRT with 3 years of androgen deprivation therapy.
  • Organs at risk (OaR) were the rectal and bladder walls, femoral heads, and large and small bowel.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Lymphatic Irradiation / methods. Prostatic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19733014.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


92. Zagaynova E, Gladkova N, Shakhova N, Gelikonov G, Gelikonov V: Endoscopic OCT with forward-looking probe: clinical studies in urology and gastroenterology. J Biophotonics; 2008 May;1(2):114-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analysed material of clinical studies of 554 patients: 164 patients with urinary bladder pathology, and 390 with gastrointestinal tract pathology.
  • We demonstrate results of EOCT application in detection of early cancer and surgery guidance, examples of combined use of OCT and fluorescence imaging.
  • The sensitivity of EOCT cancer determination in Barrett's esophagus is from 71% to 85% at different stages of neoplasia with specificity 68% for all stages.
  • As for bladder carcinoma, the sensitivity and specificity are 85% and 68%, respectively.
  • [MeSH-major] Adenocarcinoma / diagnosis. Barrett Esophagus / diagnosis. Colonic Neoplasms / diagnosis. Precancerous Conditions / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Early Detection of Cancer. Endoscopy / methods. Humans. Sensitivity and Specificity. Tomography, Optical Coherence / instrumentation

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19343643.001).
  • [ISSN] 1864-0648
  • [Journal-full-title] Journal of biophotonics
  • [ISO-abbreviation] J Biophotonics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


93. Kodama K, Mizuno T, Imahori T, Ida M, Matsubara F: Concurrent diagnosis of urothelial carcinoma and squamous cell carcinoma of the bladder in a patient with a vesicorectal fistula from invasive rectal cancer. Int J Urol; 2006 Mar;13(3):296-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent diagnosis of urothelial carcinoma and squamous cell carcinoma of the bladder in a patient with a vesicorectal fistula from invasive rectal cancer.
  • A 47-year-old man underwent a low anterior resection of the rectosigmoid colon with en bloc cystoprostatectomy for vesicorectal fistula due to a locally advanced rectal cancer.
  • Histopathological examination of the bladder revealed two additional primary malignancies: urothelial carcinoma and squamous cell carcinoma.
  • To our knowledge, this is the first reported case of two histologically distinct urothelial malignancies that were diagnosed during a work up of vesicorectal fistula due to adenocarcinoma of the rectum.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Neoplasms, Multiple Primary / diagnosis. Rectal Fistula / etiology. Rectal Neoplasms / diagnosis. Urinary Bladder Fistula / etiology. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Sigmoidoscopy


94. van Onna IE, Oddens JR, Kok ET, van Moorselaar RJ, Bosch JL, Battermann JJ: External beam radiation therapy followed by interstitial radiotherapy with iridium-192 for solitary bladder tumours: results of 111 treated patients. Eur Urol; 2009 Jul;56(1):113-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] External beam radiation therapy followed by interstitial radiotherapy with iridium-192 for solitary bladder tumours: results of 111 treated patients.
  • BACKGROUND: Evaluation of bladder-preserving treatment protocol.
  • OBJECTIVE: To evaluate the long-term results of iridium-192 brachytherapy-based bladder-sparing treatment strategy in patients with solitary invasive bladder tumours.
  • DESIGN, SETTING, AND PARTICIPANTS: We performed a retrospective analysis of 111 patients with solitary T1G3-T2Gall bladder tumours (< or = 5 cm), who were treated with iridium-afterloading brachytherapy between February 1988 and May 2007.
  • Nineteen patients died of bladder cancer after a mean follow-up period of 2.9 yr (range: 0.5-9.0).
  • Bladder function was able to be preserved in 99 of 111 patients (89%).
  • CONCLUSIONS: In patients with solitary stage T1-T2 bladder cancer (< or = 5 cm) who refuse radical cystectomy or who are poor candidates for major surgical procedures, this modality is a valuable treatment alternative.
  • [MeSH-major] Brachytherapy. Carcinoma / mortality. Carcinoma / radiotherapy. Iridium Radioisotopes / therapeutic use. Urinary Bladder Neoplasms / mortality. Urinary Bladder Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Aged. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Disease-Free Survival. Female. Follow-Up Studies. Humans. Hydronephrosis / etiology. Ileus / etiology. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome. Urinary Incontinence, Urge / etiology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2009 Jul;56(1):122 [18722047.001]
  • [CommentIn] Eur Urol. 2009 Jul;56(1):121 [18722045.001]
  • (PMID = 18722048.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Iridium Radioisotopes
  •  go-up   go-down


95. Falkensammer C, Gozzi C, Hager M, Maier H, Bartsch G, Höltl L, Rehder P: Late occurrence of bilateral tuberculous-like epididymo-orchitis after intravesical bacille Calmette-Guérin therapy for superficial bladder carcinoma. Urology; 2005 Jan;65(1):175
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late occurrence of bilateral tuberculous-like epididymo-orchitis after intravesical bacille Calmette-Guérin therapy for superficial bladder carcinoma.
  • We report a case of bilateral tuberculous-like epididymo-orchitis occurring 3 years after intravesical bacille Calmette-Guérin instillation therapy in an 83-year-old patient with proven superficial bladder carcinoma.
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Administration, Intravesical. Aged. Aged, 80 and over. Carcinoma in Situ / therapy. Carcinoma, Transitional Cell / therapy. Combined Modality Therapy. Humans. Instillation, Drug. Male. Neoplasms, Multiple Primary. Orchiectomy. Prostatic Neoplasms / radiotherapy. Prostatic Neoplasms / surgery. Time Factors. Transurethral Resection of Prostate. Tuberculoma / etiology. Tuberculoma / surgery. Urinary Bladder Neoplasms / therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667898.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCG Vaccine
  •  go-up   go-down


96. Uramoto H, Yamada S, Hanagiri T: Clinicopathological characteristics of resected adenosquamous cell carcinoma of the lung: risk of coexistent double cancer. J Cardiothorac Surg; 2010;5:92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics of resected adenosquamous cell carcinoma of the lung: risk of coexistent double cancer.
  • BACKGROUND: adenosquamous carcinoma (ADSQ) of non-small cell lung cancer (NSCLC) is a rare disease and the biological behavior and clinicopathological characteristics have not yet been thoroughly described.
  • METHOD: This study reviewed the patient charts of 11 (1.6%) ADSQ cases among 779 patients with primary lung cancer who underwent a lung resection.
  • Five patients had coexistent double cancer including 2 gastric, 1 rectal, 1 prostate and 1 bladder cancer.
  • ADSQ was found more frequently in older patients, with advanced stage, advanced T status, and lymph node metastases than adenocarcinoma (AD).
  • The proportion with coexistent double cancer of AD, SQ, and ADSQ were 21.1, 17.6, and 45.5%, respectively.
  • ADSQ had a significantly correlation with double cancer (ADSQ vs. non- ADSQ p = 0.03).
  • CONCLUSIONS: In this study, cases with ADSQ showed no significantly prognostic difference in comparison to AD and SQ.
  • However, surgeons must be cautious of any coexistent double cancer because approximately half of all patients with ADSQ of the lung have double cancer.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1996 Apr;109(4):989-94 [8635382.001]
  • [Cites] Cancer Invest. 1993;11(6):641-51 [8221196.001]
  • [Cites] Oncol Rep. 1998 Jul-Aug;5(4):861-5 [9625833.001]
  • [Cites] Scand Cardiovasc J. 1999;33(1):29-32 [10093856.001]
  • [Cites] Respir Med. 2006 Dec;100(12):2073-84 [17056245.001]
  • [Cites] Ann Thorac Surg. 2007 Aug;84(2):702-7 [17643676.001]
  • [Cites] Med Oncol. 2009;26(1):27-31 [18483884.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1289-98 [10751354.001]
  • [Cites] Jpn J Cancer Res. 1999 Nov;90(11):1244-7 [10622536.001]
  • [Cites] Chest. 2000 Feb;117(2):374-9 [10669677.001]
  • [Cites] Ann Thorac Surg. 2003 Jun;75(6):1740-4 [12822609.001]
  • [Cites] Natl Cancer Inst Monogr. 1985 Dec;68:219-42 [4088299.001]
  • [Cites] Ann Thorac Surg. 1987 Nov;44(5):462-6 [3675050.001]
  • [Cites] Am Rev Respir Dis. 1990 Jul;142(1):19-23 [2368969.001]
  • [Cites] Cancer. 1991 Feb 1;67(3):649-54 [1985759.001]
  • [Cites] Am J Clin Pathol. 1992 May;97(5):678-85 [1575214.001]
  • [Cites] Ann Thorac Surg. 1993 Mar;55(3):593-6 [8452418.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • (PMID = 21034441.001).
  • [ISSN] 1749-8090
  • [Journal-full-title] Journal of cardiothoracic surgery
  • [ISO-abbreviation] J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclic AMP-Dependent Protein Kinase RIalpha Subunit
  • [Other-IDs] NLM/ PMC2987925
  •  go-up   go-down


97. Yi SK, Yoder M, Zaner K, Hirsch AE: Palliative radiation therapy of symptomatic recurrent bladder cancer. Pain Physician; 2007 Mar;10(2):285-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative radiation therapy of symptomatic recurrent bladder cancer.
  • RT is effective at palliating both locally advanced and metastatic cancer, including related symptoms of pain, bleeding, or obstruction.
  • With regard to bladder cancer there is some evidence of the benefit of palliative RT for the control of urinary symptoms and hematuria; however, there is little evidence for the use of palliative RT for pain associated with locally recurrent bladder cancer.
  • We report a case of locally advanced recurrent bladder cancer which was refractory to medical pain management, and was found to be highly responsive to palliative RT.
  • CASE REPORT: An 80-year-old woman with recurrent bladder cancer and intractable pelvic pain refractory to oral and transdermal pain medications, received palliative pelvic RT to a dose of 50 Gy (5000 cGy) in 25 fractions with complete resolution of pain.
  • The patient was originally found to have dysuria, frequency, and hematuria, secondary to an invasive high grade transitional cell carcinoma of the bladder with an adenocarcinoma component, AJCC pT2b N1 M0 Stage IV, for which she underwent a radical cystectomy, total abdominal hysterectomy, bilateral salpingo-oophorectomy, partial vaginectomy, and ileal conduit reconstruction.
  • Ultimately a pain medication regimen of 200mcg transdermal fentanyl patch q2 days, oxycontin 20mg bid, oxycodone 5 - 10mg q 4 hours, ibuprofen 400mg q 8 hours, and gabapentin 600mg TID was not effective in controlling pain.
  • CONCLUSIONS: Palliative radiation therapy has been well studied in the setting of bone metastases and treatment of hematuria for locally advanced bladder cancer.
  • There is little data that we are aware of on the use of RT for pain control with patients that have recurrent, locally advanced bladder cancer.
  • RT is an excellent option for pain management in recurrent bladder cancer and should be offered to patients whose pain is not otherwise optimally controlled.
  • Palliative RT is an important component in the multimodality approach to cancer pain management and optimization of quality of life.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Pain / radiotherapy. Palliative Care / methods. Urinary Bladder Neoplasms / radiotherapy


98. Chen SW, Liang JA, Hung YC, Yeh LS, Chang WC, Yang SN, Lin FJ: Geometrical sparing factors for the rectum and bladder in the prediction of grade 2 and higher complications after high-dose-rate brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys; 2009 Dec 1;75(5):1335-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Geometrical sparing factors for the rectum and bladder in the prediction of grade 2 and higher complications after high-dose-rate brachytherapy for cervical cancer.
  • PURPOSE: This study aimed to assess the predictive values of geometrical sparing factors for the rectum and bladder in high-dose-rate intracavitary brachytherapy (HDRICB) for Grade 2 and higher late sequelae in patients with cervical cancer.
  • In all, 32 patients (8.2%) had Grade 2 or higher late bladder complications (14 Grade 2, 16 Grade 3, and 2 Grade 4).
  • Multivariate analysis demonstrated a high risk of rectal sequelae in patients who developed bladder complications (p = 0.0004, hazard ratio 3.54) and had a rectal GSF greater than 0.7 (p = 0.01, hazard ratio 1.99).
  • The high risk factors for bladder complications were development of rectal complications (p = 0.0004, hazard ratio 3.74), concurrent chemotherapy (p = 0.0001, relative risk 3.94), and a bladder GSF greater than 0.9 (p = 0.01, hazard ratio, 2.53).
  • CONCLUSION: This study demonstrates the predictive value of GSFs in HDRICB for cervical cancer.
  • Patients with rectal GSFs greater than 0.7 or bladder GSFs greater than 0.9 are at risk for Grade 2 and higher late sequelae.
  • [MeSH-major] Brachytherapy / adverse effects. Radiation Injuries / prevention & control. Rectum / radiation effects. Urinary Bladder / radiation effects. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / radiotherapy. Female. Humans. Iridium Radioisotopes / therapeutic use. Middle Aged. Radiotherapy Dosage. Reference Values. Regression Analysis. Risk Factors


99. Pukkala E, Martinsen JI, Lynge E, Gunnarsdottir HK, Sparén P, Tryggvadottir L, Weiderpass E, Kjaerheim K: Occupation and cancer - follow-up of 15 million people in five Nordic countries. Acta Oncol; 2009;48(5):646-790
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occupation and cancer - follow-up of 15 million people in five Nordic countries.
  • We present up to 45 years of cancer incidence data by occupational category for the Nordic populations.
  • The study covers the 15 million people aged 30-64 years in the 1960, 1970, 1980/1981 and/or 1990 censuses in Denmark, Finland, Iceland, Norway and Sweden, and the 2.8 million incident cancer cases diagnosed in these people in a follow-up until about 2005.
  • All Nordic countries have a nation-wide registration of incident cancer cases during the entire study period.
  • For the present study the incident cancer cases were classified into 49 primary diagnostic categories.
  • The observed number of cancer cases in each group of persons defined by country, sex, age, period and occupation was compared with the expected number calculated from the stratum specific person years and the incidence rates for the national population.
  • For all cancers combined (excluding non-melanoma skin cancer), the study showed a wide variation among men from an SIR of 0.79 (95% confidence interval 0.66-0.95) in domestic assistants to 1.48 (1.43-1.54) in waiters.
  • Mesothelioma was the cancer type showing the largest relative differences between the occupations.
  • Outdoor workers such as fishermen, gardeners and farmers had the highest risk of lip cancer, while the lowest risk was found among indoor workers such as physicians and artistic workers.
  • Studies of nasal cancer have shown increased risks associated with exposure to wood dust, both for those in furniture making and for those exposed exclusively to soft wood like the majority of Nordic woodworkers.
  • For nasal adenocarcinoma, the SIR in males was as high as 5.50 (4.60-6.56).
  • Male waiters and tobacco workers had the highest risk of lung cancer, probably attributable to active and passive smoking.
  • Among women, tobacco workers and engine operators had a more than fourfold risk as compared with the lung cancer risk among farmers, gardeners and teachers.
  • The occupational risk patterns were quite similar in all main histological subtypes of lung cancer.
  • Bladder cancer is considered as one of the cancer types most likely to be related to occupational carcinogens.
  • Waiters had the highest risk of bladder cancer in men and tobacco workers in women, and the low-risk categories were the same ones as for lung cancer.
  • The highest risks of liver cancer were seen in occupational categories with easy access to alcohol at the work place or with cultural traditions of high alcohol consumption, such as waiters, cooks, beverage workers, journalists and seamen.
  • The risk of colon cancer has been related to sedentary work.
  • The findings in the present study did not strongly indicate any protective role of physical activity.
  • Colon cancer was one of the cancer types showing the smallest relative variation in incidence between occupational categories.
  • The occupational variation in the risk of female breast cancer (the most common cancer type in the present series, 373 361 cases) was larger, and there was a tendency of physically demanding occupations to show SIRs below unity.
  • Women in occupations which require a high level of education have, on average, a higher age at first child-birth and elevated breast cancer incidence.
  • In male breast cancer (2 336 cases), which is not affected by the dominating reproductive factors, there was a suggestion of an increase in risk in occupations characterised by shift work.
  • Night-shift work was recently classified as probably carcinogenic, with human evidence based on breast cancer research.
  • The most common cancer among men in the present cohort was prostate cancer (339 973 cases).
  • The present study shows that the risk of cancer, even under these circumstances, is highly dependent on the person's position in the society.
  • This publication is the first one from the extensive Nordic Occupational Cancer (NOCCA) project.
  • Subsequent studies will focus on associations between specific work-related factors and cancer diseases with the aim to identify exposure-response patterns.
  • In addition to the cancer data demonstrated in the present publication, the NOCCA project produced Nordic Job Exposure Matrix (described in separate articles in this issue of Acta Oncologica) that transforms information about occupational title histories to quantitative estimates of specific exposures.


100. Araki M, Manoharan M, Vyas S, Nieder AM, Soloway MS: A pelvic drain can often be avoided after radical retropubic prostatectomy--an update in 552 cases. Eur Urol; 2006 Dec;50(6):1241-7; discussion 1246-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The routine placement of a pelvic drain following radical retropubic prostatectomy (RRP) may not be required.
  • METHODS: RRP was performed in 552 consecutive patients with clinically localised adenocarcinoma of the prostate between January 2002 and June 2005.
  • After the prostate was removed and the anastomotic sutures tied, the bladder was gently filled with approximately 50 ml of saline through the urethral catheter.
  • If there was no leak, a drain was not placed.
  • RESULTS: A drain was not placed in 419 (76%) of the 552 patients.
  • There were 27 (5%) immediate postoperative complications and no significant difference between the two groups (D+, 6%; D-, 5%; p=0.629): three (1%) patients who did not have a drain had a urinoma, one (1%) who had a drain had a lymphocele, and two (2%) who had a drain had a small pelvic haematoma.
  • CONCLUSIONS: If the bladder neck is preserved or meticulously reconstructed, there may be little extravasation and, thus, routine drainage is unnecessary.
  • Our 4-year experience indicates that morbidity is not increased by omitting a drain from the pelvic cavity after RRP in properly selected cases.
  • [MeSH-major] Adenocarcinoma / surgery. Drainage / contraindications. Pelvis / surgery. Prostatectomy. Prostatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16797119.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down






Advertisement